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Abstract and Key Words 
 This thesis describes the work carried out on two projects. The first chapter of the thesis 
discusses the application of the second generation Co(nmp)2 catalyst towards the oxidative 
cyclization of tertiary pentenols through a modified Mukaiyama aerobic oxidative cyclization 
procedure.  
The second chapter describes the progress made towards the synthesis of β-carboline 
alkaloids. The total synthesis of the alkaloid natural product cyclocapitelline is detailed along 
with the formal synthesis of the natural product chrysotricine.  
 
Key Words: Mukaiyama aerobic oxidative cyclization, trans-2,5,5-tetrahydrofurans, natural 
product, chrysotricine, cyclocapitelline, cross-metathesis.  
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Chapter One: Synthesis of trans-2,5,5-tetrahydrofurans 
1.0 Introduction 
 The tetrahydrofuran (THF) ring is a 5 membered cyclic ether which is one of the most 
commonly used organic solvents. THF is much more than a simple solvent however, as 
substitution about the ring provides access to a multitude of products with differing regio and 
stereochemical arrangements. These derivatives represent a prominent structural motif within the 
chemistry of natural products and pharmaceuticals as there are an ever growing number of 
natural products being isolated which contain the THF moiety. Many of these compounds 
possess biological activity and the potential to be advanced within the pharmaceutical 
development process.
1
 This chapter will outline progress towards the synthesis of trans-2,5,5-
THFs through a Mukaiyama aerobic oxidative cyclization procedure employing a second 
generation cobalt catalyst.
1
 The research in this chapter was carried out in collaboration with 
colleagues Dr. Andrew Stevens and Mr. Cory Palmer. Results are those generated by the author 
unless otherwise attributed. 
1.1 Common Methods for THF Synthesis 
 The prevalence of the THF ring in natural products chemistry has driven considerable 
synthetic efforts towards the synthesis of THFs. A multitude of procedures can be applied to 
forming THFs with some having broad substrate applicability and others finding more niche 
applications.
2
 
 When considering the asymmetric synthesis of THFs, it is often beneficial to make use of 
prochiral starting materials, which enable the synthesis of chiral material either directly or in a 
stepwise manner. Prochiral olefins can be asymmetrically epoxidized through methods such as 
Sharpless or Shi epoxidations and then opened either intra or intermolecularly. This strategy is 
often amenable to cascade reactions sequences allowing for the synthesis of several THFs in one 
                                                          
1
 trans-2,5,5-THFs have been named according to the Cahn-Ingold-Prelog priorities of the substituents at the 2 and 5 
positions of the THF ring. The orientation of the highest priority substituents at these positions dictates the cis or 
trans label indicated for the THF. 
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process. Hoye employed such a procedure in his synthesis of the natural product (+)-Parviflorin 
(Scheme 1.0). The synthesis made use of a double Sharpless epoxidation and Sharpless 
dihydroxylation sequence to form the bis THF core of the natural product as a single 
diastereomer 1-3.
3
  
 
Scheme 1.0. Synthesis of (+)-Parviflorin core. 
 
 
  
 Reactions of this type can be tuned with different electrophilic and nucleophilic partners in 
order to accommodate synthetic goals. The disadvantage of this method is that specific substrate 
classes and multistep formation of asymmetric material are required. In addition, the 
stereochemistry of both nucleophilic and electrophilic partners must be set initially to achieve 
optimal diastereoselectivity.   
 It is beneficial to conduct one pot THF forming reactions from prochiral molecules rather 
than employing multiple synthetic steps designed to set stereocenters before THF formation. 
Such transformations require fewer stereochemical setting steps because stereochemistry is set 
during the course of the reaction. The oxidative cyclization of unsaturated alcohols to form THFs 
is a one pot product forming procedure frequently employed in synthesis.  
 The advantages to this method are its high substrate tolerance, the general simplicity of 
preparing starting materials, and the high degree of diastereoselectivity in product formation.  
3 
 
 
 
 Oxidative cyclizations of unsaturated alcohols make use of catalytic amounts of transition 
metal complexes in the presence of stoichiometric oxidants, to convert bishomoallylic alcohols 
into THFs with varying degrees of substitution.  
 Some early work in this area was conducted by Hosokawa who developed a method for the 
oxidative cyclization of vinyl pentenols to afford 2-vinyltetrahydrofurans in low yield but with 
good to excellent diastereoselectivity (Scheme 1.2).
4
  
 
Scheme 1.2. Hosokawa oxidative cyclization. 
 
 
 
 This methodology employed Pd(OAc)2 catalyst with oxygen acting as the stoichiometric 
oxidant. Cu(OAc)2 was present in a stiochiometric amount in order to re-oxidize the Pd(0) to the 
active Pd(II) catalyst. The use of oxygen as a stoichiometric oxidant is another advantage to this 
methodology as it is a cheap, readily available reagent which lowers the amount of waste being 
produced in such reactions. Later optimizations with Pd species would allow for the removal of 
the Cu oxidant and limit waste production even further.
5
 
 Palladium catalyzed oxidative cyclizations can be replaced with less expensive alternatives 
while still maintaining good yields and high levels of diastereoselectivity. The Hartung group has 
demonstrated this with the development of Schiff-base vanadium complexes, which have been 
used in conjuction with tert-butyl hydroperoxide as the stoichiometric oxidant to effect the 
formation of cis 2,5-THFs (Scheme 1.3).
6
  
 
 
4 
 
 
 
Scheme 1.3.  Hartung’s synthesis of cis-2,5-THFs. 
 
 
 
 Given that there are a number of oxidative cyclization reactions capable of forming THFs, 
the method to be employed in a synthesis is dependent upon the diastereoselectivity of the 
method, the potential for higher yields and the substrate tolerance of the transformation.  
1.2 The Mukaiyama Aerobic Oxidative Cyclization  
 Within the area of THF chemistry, the Mukaiyama aerobic oxidative cyclization stands out 
as prominent transformation for the formation of THFs bearing substituents with trans 
stereochemistry at the 2 and 5 positions.
7
 The methodology developed by Mukaiyama and co-
workers employs a Co catalyst and oxygen as a stoichiometric oxidant to convert bishomoallylic 
alcohols into trans-2,5-THFs (Scheme 1.4) in good yield and excellent levels of 
diastereoselectivity (>99:1 dr).  
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Scheme 1.4. The Mukaiyama aerobic oxidative cyclization. 
 
6
 
 
 THF rings bearing trans stereochemistry at the 2 and 5 positions can be found in a range of 
natural products. Some notable examples include the amphidinolide family of natural products, 
along with the haterumalides and the biselides (Figure 1.0). Several members of these large 
families possess biological activities including haterumalide NA which was found to be 
cytotoxic towards leukemia cell line (P338) and Amphidinolide C which exhibits potent 
cytotoxicity against murine lymphoma and human epidermoid carcinoma cells.
8
 The biologically 
active nature of these natural products make their synthesis more than just a synthetic challenge, 
but also a practical endeavor from a pharmaceutical standpoint.  
 
Figure 1.0. Natural products containing trans-2,5-THFs. 
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 The original Mukaiyama procedure was effective for the cyclization of a wide variety of 
bishomoallylic alcohols bearing diverse functionalities and was very selective in the formation of 
trans stereochemistry at the 2 and 5 positions of the resulting products (>99% trans). The 
primary alcohol formed in the cyclization also acts as a useful synthetic handle for further 
transformations. Unfortunately, the original Mukaiyama procedure did come with setbacks to its 
applicability. The original modp catalyst was difficult to separate through conventional flash 
chromatography, making purification of substrates challenging. Yields of the cyclized products 
were moderate to good but left room for improvement and a stoichiometric amount of tert-butyl 
hydroperoxide was required for optimal yields and reaction times.  
1.3 Mechanistic Investigation of the Oxidative Cyclization 
 The origin of trans selectivity in the Mukaiyama cyclization was examined by Mukaiyama 
in his original publication on the method (Scheme 1.5).7 He proposed that pentenol 1 interacts 
with oxygen and Co(modp)2 to form a radical coordination compound 2. This coordination 
compound then cyclizes via radical cyclization to form Co species 3 with trans orientation at the 
2 and 5 positions. The trans stereochemistry arises from the R group and CoL2 adopting a trans 
orientation at the 2 and 5 positions in order to avoid steric interactions. Oxygen then inserts into 
the Co-C bond of 3 forming a cobalt peroxide intermediate. Reductive cleavage by the iPrOH 
solvent affords the THF methanol product 4.  
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Scheme 1.5. Mukaiyama’s proposed mechanism. 
 
 
 The Mukaiyama mechanism serves to explain the origin of the trans stereochemistry in the 
products but is limited in its explanation of radical formation, and regeneration of the Co catalyst 
following reductive cleavage.  
 The role of tBuOOH remains unclear, however Mukaiyama speculates that the peroxide may 
accelerate the formation of the radical intermediate 2. It may also assist in re-oxidizing the cobalt 
catalyst.  
 A publication by Hartung shed new light on the mechanistic pathway of the Mukaiyama 
cyclization (Scheme 1.6).
9
 In the mechanism, Hartung proposes that the Co(II) catalyst, in the 
presence of oxygen is oxidized to a radical Co(III) species able to coordinate to the pentenol 
oxygen forming 1. Single electron oxidation of the pendant alkene provides radical cation 2. 5-
exo attack of the hydroxyl group onto the carbocation forms THF methyl radical 3. The observed 
trans stereochemistry of the products arises during the ring closure step where a chair like 
transition state forces substituents at the 2 and 5 positions into a trans orientation to limit steric 
interactions. In the presence of an H atom donor radical THF species 3 will afford THF methanol 
product and hydroxy cobalt(II) complex 4. 
 
8 
 
 
 
 
Scheme 1.6. Hartung mechanism for the Mukaiyama oxidative cyclization. 
 
 
 
 Catalyst regeneration is proposed to occur via coordination of a solvent molecule to hydroxy 
cobalt complex 4. A hydride shift from the solvent molecule would then produce 
hydridocobalt(III) complex 5 releasing water and acetone as byproducts. In the presence of 
oxygen, cobalt complex 5 can then be converted to Co(II) which is then able to re-enter the 
catalytic cycle (Scheme 1.7).  
 
Scheme 1.7. Completion of catalytic sequence. 
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1.4 The Co(nmp)2 Catalyst 
 Many of the problems associated with the original Mukaiyama catalyst and cyclization 
procedure were addressed by the Pagenkopf group through the development of a second 
generation Co catalyst.
10
 The Co(nmp)2 catalyst (Figure 1.2) was more easily separated than the 
Co(modp)2 catalyst thereby greatly simplifying purification. Co(nmp)2 could be removed 
through extraction using a pH 4 phosphate buffer wash of the organic layer. With acid sensitive 
substrates the N-methyl nitrogen could be quaternized with methyl iodide allowing for the 
catalyst to be removed through extraction. It was also discovered that the catalyst could be 
removed through a simple filtration through a silica plug with excess solvent. 
  
 
 
Figure 1.2. Co(nmp)2 
 
 The Co(nmp)2 catalyst was found to be more active than Co(modp), providing trans-2,5-
THFs in higher yields than the original system while still achieving excellent levels of 
diastereoselectivity (Table 1.0). A lower catalyst loading 10% Co(nmp)2 vs 20% Co(modp)2 was 
effective at catalyzing the oxidative cyclizations and stoichiometric amounts of tert-butyl 
hydroperoxide were not required. Co(nmp)2 has also been employed in the total synthesis of 
several natural products including Pagenkopf’s syntheses of the C(1)-C(9) fragment of 
amphidinolide C, and Fürstner’s total synthesis of amphidinolide F.11 
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Table 1.0. Comparrison of Co(nmp)2 to Co(modp)2 in the synthesis of trans-2,5-THFs. 
 
 
Entry Product 
Co(modp)2 
yield (%) 
Co(nmp)2 
yield (%) 
1 
 
58 90 
2 
 
57 95 
3 
 
76 91 
4 
 
70 90 
5 
 
42 88 
 
1.5 Synthesis of trans-2,5,5-THFs 
 Like trans-2,5-THFs, related trans-2,5,5-THFs are also frequently found in natural products. 
Methods for their synthesis under oxidative cyclization conditions have seen limited exposure 
within the literature. Work by the Hartung group has shown that such transformations can be 
accomplished under catalysis with a bis[3-trifluoroacetylcampherato(−1)]cobalt(II) complex 
although the diastereoselectivity and yield of the product THFs were limited (Scheme 1.8). 
 
 
11 
 
 
 
Scheme 1.8. Hartung’s synthesis of trans-2,5,5-THFs. 
 
 
 
 In an effort to extend the methodology originally developed by Mukaiyama as well as 
expand on the scope of Co(nmp)2 catalyzed oxidative cyclizations the Pagenkopf group chose to 
apply Co(nmp)2 to the cyclization of tertiary bishomoallylic alcohols (Equation 2, Scheme 1.9).  
 
Scheme 1.9. Oxidative cyclizations of secondary and tertiary bishomoallylic alcohols.  
 
 
 
1.6 Results and Discussion 
 The synthesis of the cyclization substrates was carried out with Grignard additions to 
ketones, aldehydes, or epoxides (Scheme 1.10, equations 1, 2, 3 respectively). In the first case 
(eq 1), the addition of the Grignard reagent formed from 4-bromo-1-butene with a variety of 
ketones allowed quick access to the corresponding tertiary pentenols. Although this approach 
12 
 
 
 
produced several different pentenols, the use of enolizable ketones proved problematic and 
hindered product formation in some cases. To overcome this problem, additions of the Grignard 
reagent of 4-bromo-1-butene were carried out on a variety of aldehydes followed by an oxidation 
and second Grignard addition to the resulting ketone (eq 2). When the appropriate terminal 
epoxide could be synthesized epoxide openings were carried out employing allyl magnesium 
bromide to afford secondary pentenols. These pentenols were then oxidized to the corresponding 
ketone followed by a second Grignard addition to access the tertiary pentenol (eq 3).  
 
Scheme 1.10. Synthesis of cyclization substrates. 
  
 
. 
 Initial efforts towards the cyclization of tertiary bishomoallylic alcohols to form trans-2,5,5-
THFs were begun by co-workers Dr. Andrew Stevens and Mr. Cory Palmer. They found that the 
conditions established for the synthesis of secondary bishomoallylic alcohols proved to be 
ineffective when applied to tertiary alcohols. This problem was circumvented by the 
establishment of a modified procedure wherein the Co(nmp)2 catalyst was pre-oxidized with 
tBuOOH under oxygen atmosphere prior to substrate introduction. The pre-oxidized catalyst was 
found to be more active and was able to catalyze the cyclization of tertiary pentenols. Stevens 
and Palmer found that optimal conditions were achieved with a pre-oxidized catalyst loading of 
17.5% in sec-butanol (0.5 M with respect to starting material) with heating to 80 °C for a period 
of 16 h. With the optimized set of conditions in hand, a substrate scope was investigated (Table 
1.1).  
13 
 
 
 
 
Table 1.1. Initial Substrate Scope. 
 
 
 
Entry Starting Material Product 
Yield % 
(*)a 
d.r. 
1 
  
63 
(72) 
7:1 
2 
 
 
42 
(48) 
5:1 
3 
  
36 
(69) 
3:1 
4 
  
25 
(32) 
2:1 
5 
  
44 
(50) 
 
- 
6 
  
39 
(73) 
 
- 
7 
  
38 
(45) 
2:1 
 
 
8 
 
  
19 
(20) 
5:1 
9 
  
44 
(50) 
2:1 
14 
 
 
 
10 
  
45 
(57) 
2:1 
a
 Yield based on recovered starting material. Yeilds for 1-20a-1-21a, 1-23a, and 1-25a reported by Cory Palmer. 
 The cyclization proved to be tolerant of a wide range of tertiary pentenols providing 
products in poor to moderate yields. Substrates with less steric bulk at the tertiary alcohol 
generally gave higher yields and better diastereotopic ratios. This can be seen when comparing 
1-18a (entry 1) and its one carbon homologue 1-19a (entry 2) where there is a drop in yield and 
selectivity and again when comparing spirocyclic products 1-22a  and 1-23a (entries 5 and 6).  
Greater steric bulk at the alcohol oxygen may effect catalyst coordination resulting in poorer 
levels of conversion and lower yields. Steric crowding at the alcohol may also result in trans 
orientation at the 2 and 5 positions becoming less favourable thus leading to a greater percentage 
of an alternate diastereomer   
 The major diastereomer was expected to arise from trans stereochemistry at the 2 and 5 
positions as the oxidative cyclization is selective for trans stereochemistry on a steric basis. The 
configuration of the minor diastereomeric constituent was unclear however it was likely a result 
of a cis orientation at the 2 and 5 positions. NOE analysis of the diastereomeric mixtures proved 
inconclusive and the nature of the stereochemical arrangement of the products would not be 
confirmed until later work on the synthesis of β-Carboline alkaloids (see chapter 2).  
 The isolated yields of the tri-substituted THF products were lower than those acquired when 
cyclizing secondary pentenols. Analysis of crude material from the cyclization of secondary 
alcohols showed consumption of starting material with in many cases the ability to acquire pure 
product following filtration. 
 When tertiary pentenols were cyclized the reaction did not go to completion and starting 
material remained however mass recovery was generally quantitative. Taking the remaining 
starting material into account, the isolated yields of the tri-substituted THFs following flash 
chromatography were lower than expected based on the yields of product calculated from NMR 
analysis of crude material. The application of a mesitylene internal standard confirmed that the 
crude yields were in fact reliable.  
15 
 
 
 
 We speculated that such a loss could be the result of product decomposition during silica gel 
chromatography. The tri-substituted ether at the 5 position the THF product presents a possible 
site for ring opening on exposure to acidic media such as silica gel through the formation of a 
stable tertiary carbocation 1 (Scheme 1.11). 
Scheme 1.11. Possible Ring Opening Mechanism. 
 
 
 
 The application of alternative purification methods such as the use of alumina, basic 
alumina, and reverse phase silica gel were ineffective at preventing loss of product on 
purification.  
 With the idea that electronics and ring opening were the problem we chose to synthesize 
THFs bearing electron withdrawing substituents at the 5 position in the hopes that the electron 
withdrawing effect would limit ring opening and product loss (Table 1.2).  
 
Table 1.2 Substituents bearing electron withdrawing functionalities. 
 
Entry Starting Material Product 
Yield % 
(*)a 
d.r. 
1 
 
 
35 
(38) 
4:1 
2 
 
 
49 
(63) 
4:1 
a
 Yield based on recovered starting material. 
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 Aryl pentenols 1-30 and 1-31 possessing para substituted electron withdrawing groups were 
cyclized providing THF products 1-30a and 1-31a respectively (entries 1 and 2). Unfortunately 
the yields of these products were in line those of alkyl and even electron rich THFs e.g. 1-26a. 
 Following these results, we chose to derivatize a crude mixture of 1-19a as a TBS ether 
(Scheme 1.12). The goal of this derivatization was to lower the polarity of the cyclized product 
and thereby limit possible detrimental interactions with the chromatographic solid phases. In 
addition derivatization might serve to limit deleterious effects arising from the free hydroxyl. 
Conversion to the TBS ether was carried out successfully, however column chromatography of 
the crude reaction mixture was still ineffective at isolating the product in high yield. 
 
Scheme 1.12. Derivatization of crude material. 
 
 
 
 A select few pentenols were cyclized under the standard conditions but with Co(modp)2 as 
the catalyst in order to make a comparison with the yields obtained with Co(nmp)2 (Table 1.3). 
As expected, the first generation catalyst was able to catalyze the cyclizations but the yields were 
substantially lower than the corresponding yields with Co(nmp)2.  
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Table 1.3. Comparrison to Co(modp)2. 
 
Entry Product 
Yield % 
Co(modp)2 
Yield % 
Co(nmp)2 
1 
 
23 
56 
 
2 
 
27 
45 
 
 
Despite the issues related to purification, the Co(nmp)2 catalyzed oxidative cyclization of 
tertiary pentenols presents significant advantages over other THF forming reactions. The 
simplicity of the required cyclization precursors, the ease of application, and the primary alcohol 
formed in the reaction make THF formation through Mukaiyama oxidative cyclization a viable 
option for use in organic synthesis.  
1.7 Conclusions and Future Work 
 This chapter has outlined the progress made towards applying the Mukaiyama oxidative 
cyclization with Co(nmp)2 towards the cyclization of tertiary pentenols. A number of THFs have 
been synthesized with reasonable to good yields and diastereotopic ratios. This work represents 
an advancement in the synthesis of trans-2,5,5-THFs by oxidative cyclization over previously 
reported procedures.  
 There is room for improvement with the methodology in terms of the yields obtained. 
Future work in this area would seek to improve yields and levels of diastereoselectivity. This 
could potentially be accomplished through modification to the catalyst system itself in order to 
more effectively tailor steric and electronic factors in the cyclization process. 
 Future would also seek to employ the cyclization methodology with Co(nmp)2 in the 
synthesis of natural products and pharmaceutical agents.  
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1.8 Experimental 
1.8.1 General Experimental Details 
All reactions were conducted under Argon atmosphere unless otherwise indicated. All 
glassware was oven dried and cooled in a desiccator prior to use. Solvents and reagents were 
purified using standard methods.
12
 All reactions were stirred with a magnetic stir bar. 
Dichloromethane, diethyl ether, and tetrahydrofuran were purified by passing solvents through 
activated alumina columns. Isopropyl alcohol was used as obtained from Caledon Laboratory 
Chemicals. All other chemicals were reagent grade and used as obtained from commercial 
sources unless otherwise noted. The progress of reactions were monitored by thin layer 
chromatography (TLC) performed on F254 silica gel plates. The plates were visualized by 
staining with potassium permanganate or ceric ammonium molybdate (CAM). Column 
chromatography was performed with Silica Flash P60 60 Å silica gel from Silicycle according to 
the Still method.
13
 
 
1
H and 
13
C NMR were acquired on 400 and 600 MHz spectrometers in deuterated 
chloroform. 
1
H NMR were referenced to residual chloroform at  7.26 ppm and the center peak 
of the triplet at  77(t) ppm for 13C NMR. When peak multiplicities are given, the following 
abbreviations are used: s, singlet; d, doublet; dd, doublet of doublets; ddd, doublet of doublet of 
doublets; dddd, doublet of doublet of doublet of doublets; ddt, doublet of doublet of triplets; t, 
triplet; q, quartet; m, multiplet; br, broad; app, apparent. EI mass spectra were obtained on a 
Finnigan MAT 8200 spectrometer at an ionizing voltage of 70 eV.  
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1.82 Experimental Details 
General Cyclization Procedure: Previously prepared Co(L)2 (0.175 mmol, 0.175 equiv) was 
placed under 1 atm O2 (balloon) and then dissolved in 3 mL iPrOH.
14
 tert-butyl hydroperoxide 
(5.74 M in isooctane, 0.03 mL, 0.175 mmol, 0.175 equiv) was added and the resulting mixture 
heated at 50 °C for 1 hr. Solvent was removed under reduced pressure yielding the pre-oxidized 
catalyst as dark green crystals. To the pre-oxidized catalyst was then added the cyclization 
precursor (1 mmol, 1 equiv) in 2 mL sec-butanol. With a condenser attached the reaction mixture 
was placed under 1 atm O2 (balloon) and heated at 80 °C for 16h. The reaction mixture was then 
concentrated under reduced pressure and the resulting oil diluted with ethyl acetate and filtered 
through a silica gel (3.5 cm) and Celite (1 cm) bilayer pad. The pad was flushed with excess 
ethyl acetate (~75 mL) following filtration. The filtrate was concentrated under reduced pressure 
and then purified by flash chromatography.  
1.83 Cyclization Substrates 
Compounds 1-18 – 1-26 were prepared by Cory Palmer and Andrew Stevens.  
Compound 1-33 
To a 250 mL round bottom flask charged with CH2Cl2 (50 mL) at 0 °C 
were combined TBSCl (5.79 g, 38 mmol, 1.2 eq), imidazole (5.3 mL, 96 
mmol, 3 eq), and 1 drop of DMF forming an opaque white solution. Glycidol (2.3 mL, 32 mmol, 
1 equiv) in CH2Cl2 (50 mL) was then introduced. After 1 hr at 0 °C the reaction was poured into 
half-saturated NaHCO3 (30 mL). The layers were separated and the aqueous extracted with 
CH2Cl2 (3 x 50 mL). The combined organic layers were washed with brine, dried over MgSO4, 
filtered through Celite and concentrated under reduced pressure to afford TBS protected glycidol 
(5.05 g, 27 mmol, 1 eq) requiring no purification. The crude material was transferred to a 250 
mL round bottom equipped with a condenser and then diluted with ether (125 mL). The resulting 
solution was cooled to 0 °C. Allylmagenisum bromide (1M in ether, 40.1 mL, 40.1 mmol, 1.5 
equiv) was introduced and the condenser rinsed with ether (5 mL). The cooling bath was 
removed. After 1 h excess Grignard reagent was quenched with half-saturated NH4Cl (30 mL). 
The layers were separated and the aqueous extracted with ether (3 x 50 mL). The combined 
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organic layers were washed with brine, dried over MgSO4, filtered through Celite and 
concentrated under reduced pressure. The crude residue (6.15 g, 27 mmol, 1 eq) was taken up in 
CH2Cl2 (125 mL). iPr2NEt (32 mL, 186 mmol, 7 eq) and DMSO (9.4 mL, 133 mmol, 5 eq) were 
introduced and the solution cooled to 0 °C. SO3•Pyr complex (12.7 g, 80 mmol, 3 eq) was then 
introduced and the cooling bath removed. After 30 min half-saturated NaHCO3 (30 mL) was 
introduced. The layers were separated and the aqueous extracted with CH2Cl2 (3 x 50 mL). The 
combined organic layers were washed with brine, dried over MgSO4, and concentrated under 
reduced pressure. The residue was purified by flash chromatography (5% EtOAc/Hexanes) to 
afford the title compound (5.15 g, 56% over 3 steps) as a clear colourless oil. Rf
 
0.64 (20% 
EtOAC/Hexanes);
 1
H NMR (400MHz, CDCl3) δ 5.82 (dddd, J = 16.8, 10.2, 6.6, 6.6 Hz, 1 H), 
5.01-5.06 (m, 1 H), 4.96-5.00 (m, 1 H), 4.16 (s, 2 H), 2.61 (t, J = 7.0 Hz, 2 H) 2.31-2.37 (m, 2 
H), 0.92 (s, 9 H), 0.09 (s, 6 H); 
13
C NMR (101 MHz, CDCl3) δ 210.4, 137.1, 115.2, 69.4, 37.5, 
27.2, 25.8, 18.3, -5.5; HRMS m/z 229.1618 (calc for C12H24O2Si+H
+
, 229.1618). 
Compound 1-27 
Ketone 1-33 (5.13 g, 22 mmol, 1 eq) was taken up in ether (125 mL) in a 
flask equipped with a condenser. Methylmagnesium bromide (3M in ether, 
9 mL, 27 mmol, 1.2 eq) was introduced dropwise at room temperature. After 2 h excess Grignard 
reagent was quenched by addition of half-saturated NH4Cl (30 mL). The layers were separated 
and the aqueous extracted with ether (3 x 50 mL). The combined organic layers were washed 
with brine, dried over MgSO4, filtered through Celite and concentrated under reduced pressure. 
The residue was purified by flash chromatography (1% EtOAc/Hexanes - 3% EtOAc/Hexanes) 
to afford the title compound as a clear colourless oil (3.42 g, 63%). Rf
  
0.73 (30% 
EtOAC/Hexanes);
 1
H NMR (400MHz, CDCl3) δ 5.84 (dddd J = 16.8, 10.2, 6.6, 6.6 Hz, 1 H), 
5.00-5.05 (m, 1 H), 4.92-4.96 (m, 1 H), 3.43 (d, J = 9.8 Hz, 1 H), 3.38 (d, J = 9.4 Hz, 1H), 2.33 
(s, 1 H), 2.06-2.20 (m, 2 H), 1.47-1.63 (m, 2 H), 1.12 (s, 3 H), 0.91 (s, 9 H), 0.07 (s, 6 H); 
13
C 
NMR (101 MHz, CDCl3) δ 139.06, 114.17, 72.16, 70.10, 37.64, 28.17, 25.86, 23.06, 18.28, -
5.46; HRMS m/z 245.1930 (calc for C13H28O2Si+H
+
, 245.1931). 
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Compound 1-34 
 Manually ground magnesium turnings (0.43 g, 18 mmol, 1.8 eq) and 
an I2 crystal were combined in a round bottom flask equipped with a 
condenser. Ether (100 mL) was introduced and the resulting suspension 
brought to reflux. 4-bromo-1-butene (1.3 mL, 13 mmol, 1.3 eq) was introduced through the 
condenser and the condenser rinsed with ether (1 mL). After 1 h the resulting homoallyl 
magnesium bromide was allowed to cool to room temperature. 4-cyanobenzaldehyde (1.31 g, 10 
mmol, 1 eq) in Ether (10 mL) and THF (3.5 mL) was introduced through the condenser and the 
reaction monitored for completion by TLC. On completion excess Grignard reagent was 
quenched with half-saturated NH4Cl (30 mL). The layers were separated and the aqueous 
extracted with ether (3 x 30 mL). The combined organic layers were washed with brine, dried 
over MgSO4, and concentrated under reduced pressure. The crude residue (1.69 g, 9 mmol, 1 eq) 
was taken up in CH2Cl2 (90 mL). iPr2NEt (11 mL, 63 mmol, 7 eq) and DMSO (3.2 mL, 45 
mmol, 5 eq) were introduced and the solution cooled to 0 °C. SO3•Pyr complex (4.30 g, 27 
mmol, 3 eq) was then introduced. The cooling bath was removed. After 1 h half-saturated 
NaHCO3 (30 mL) was introduced. The layers were separated and the aqueous extracted with 
CH2Cl2 (3 x 50 mL). The combined organic layers were washed with brine, dried over MgSO4, 
and concentrated under reduced pressure. The residue was purified by flash chromatography 
(15% EtOAc/Hexanes) to afford the title compound (1.074 g, 58% over 2 steps) as a clear 
colourless oil. 
1
H NMR (600MHz, CDCl3) δ 8.04-8.05 (m, 2 H), 7.76-7.78 (m, 2 H), 5.85-5.92 
(m, 1H), 5.07-5.11 (m, 1 H), 5.02-5.04 (m, 1 H), 3.09 (t, J = 7.6 Hz, 2 H), 2.50 (dt, J = 14.1, 7.0 
Hz, 2 H); 
13
C NMR (101 MHz, CDCl3) δ 197.9, 139.8, 136.6, 132.5, 128.4, 117.9, 116.3, 115.7, 
38.0, 27.8; HRMS m/z 185.0833 (calcd for C12H11NO, 185.0841). 
Compound 1-30 
 Ketone 1-34 (1.02 g, 5.5 mmol, 1 eq), was taken up in THF (50 mL) 
and methylmagnesium bromide (3 M, 3.6 mL, 11 mmol, 2 eq) was 
introduced dropwise at room temperature. After 1.5 h excess Grignard 
reagent was quenched by the addition of half-saturated NH4Cl (30 mL). The layers were 
separated and the aqueous extracted with ether (3 x 30 mL). The combined organic layers were 
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washed with brine, dried over MgSO4, filtered through Celite and then concentrated under 
reduced pressure. The resulting crude material was purified by flash chromatography (10% 
EtOAc/Hexanes) to afford the title compound as a clear orange oil (0.97 g, 87%). Rf  0.43 (30% 
EtOAc/Hexanes);
 1
H NMR (600 MHz, CDCl3) δ 7.64 (d, J = 8.2 Hz, 2 H), 7.55 (d, J = 8.2 Hz, 2 
H), 5.77 (dddd, J = 17.0, 10.5, 6.4, 6.4 Hz, 1 H), 4.93-4.98 (m, 2 H), 2.03 – 2.08 (m, 1 H), 1.85-
1.95 (m, 3 H), 1.57 (s, 3 H); 
13
C NMR (101 MHz, CDCl3) δ 153.04, 138.09, 132.06, 125.72, 
118.91, 115.09, 110.47, 74.71, 42.82, 30.46, 28.28; HRMS m/z 201.1153 (calcd for C13H15NO, 
201.1154). 
Compound 1-35 
 Manually ground magnesium turnings (0.64 g, 27 mmol, 1.8 eq) and 
an I2 crystal were combined in a round bottom flask equipped with a 
condenser. Ether (100 mL) was introduced and the resulting suspension 
brought to reflux. 4-bromo-1-butene (2.0 mL, 19.5 mmol, 1.3 eq) was introduced through the 
condenser and the condenser rinsed with ether (1 mL). After 1 h the resulting homoallyl 
magnesium bromide was allowed to cool to room temperature. 4-trifluoromethylbenzaldehyde (2 
mL, 15 mmol, 1 eq) in Ether (10 mL) was introduced through the condenser and the reaction 
monitored for completion by TLC. On completion excess Grignard reagent was quenched with 
half-saturated NH4Cl (30 mL). The layers were separated and the aqueous extracted with ether (3 
x 30 mL). The combined organic layers were washed with brine, dried over MgSO4, and 
concentrated under reduced pressure. The crude residue (3.07 g, 13.3 mmol, 1 eq) was taken up 
in CH2Cl2 (100 mL). iPr2NEt (16 mL, 93 mmol, 7 eq) and DMSO (4.7 mL, 66.5 mmol, 5 eq) 
were introduced and the solution cooled to 0 °C. SO3•Pyr complex (6.35 g, 40 mmol, 3 eq) was 
then introduced. The cooling bath was removed. After 1.5 h half-saturated NaHCO3 (30 mL) was 
introduced. The layers were separated and the aqueous extracted with CH2Cl2 (3 x 50 mL). The 
combined organic layers were washed with brine, dried over MgSO4, and concentrated under 
reduced pressure. The residue was purified by flash chromatography (10% EtOAc/Hexanes) to 
afford the title compound as a clear colourless oil (1.68 g, 49% over 2 steps). 
1
H NMR (400 
MHz, CDCl3) δ 8.07 (d, J = 8.2 Hz, 2 H), 7.73 (d, J = 8.2 Hz, 2 H), 5.90 (dddd, J = 16.8, 10.2, 
6.6, 6.6 Hz, 1 H), 5.07-5.12 (m, 1 H), 5.01-5.05 (m, 1 H), 3.10 (t, J = 7.4 Hz, 2 H), 2.49-2.45 (m, 
2 H); 
13
C NMR (101 MHz, CDCl3) δ 198.4, 139.5, 136.8, 134.2 (q, J = 32.2 Hz), 128.3, 125.6 (q, 
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J = 3.8 Hz), 123.6 (q, J = 273.0 Hz), 115.6, 38.0, 27.9; HRMS m/z 228.0772 (calcd for 
C12H11F3O, 228.0762).  
Compound 1-31 
Ketone 1-35 (1.64 g, 7.2 mmol, 1 eq), was taken up in ether (100 mL) 
and methylmagnesium bromide (3 M in ether, 6 mL, 18 mmol, 2.5 eq) 
was introduced dropwise at room temperature. After 1 h excess 
Grignard reagent was quenched by the addition of half-saturated NH4Cl (30 mL). The layers 
were separated and the aqueous extracted with ether (3 x 30 mL). The combined organic layers 
were washed with brine, dried over MgSO4, filtered through Celite and then concentrated under 
reduced pressure. The resulting crude material was purified by flash chromatography (10% 
EtOAc/Hexanes – 20% EtOAc/Hexanes) to afford the title compound as a clear yellow oil (1.21 
g, 69%). Rf
  
0.58 (30% EtOAc/Hexanes);
  1
H NMR (600MHz, CDCl3) δ 7.60 (d, J = 8.8 Hz, 2 H), 
7.55 (d, J = 8.2 Hz, 2 H), 5.75-5.82 (m, 1 H), 4.95-4.99 (m, 2 H), 4.93-4.95 (m, 2H), 2.04-2.09 
(m, 1 H), 1.88-1.97 (m, 3 H), 1.58 (s, 3 H); 
13
C NMR (101 MHz, CDCl3) δ 151.63, 138.30, 
128.81 (q, J = 32.2 Hz), 152.22, 125.09 (q, J = 3.83 Hz), 124.38 (q, J = 272.21 Hz), 114.85, 
74.68, 42.89, 30.34, 28.30; HRMS m/z 244.1071 (calcd for C13H15F3O, 244.1075). 
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1.84 Cyclized Products 
Compounds 1-20a, 1-21a, and 1-23a were prepared by Cory Palmer and Andrew Stevens. 
Compounds 1-18a, 1-19a, 1-22a, 1-24a, and 1-25a were previously reported by Cory Palmer but 
these experiments were re-run in order to confirm results or acquire additional data for full 
characterization.  
Compound 1-18a 
The title compound was prepared according to the general cyclization 
procedure to afford a clear colourless oil (0.066, 63%) as a 7:1 mixture of 
diastereomers. Rf  0.23 (20% EtOAc/Hexanes); 
1
H NMR (600MHz, CDCl3) δ 7.43 – 7.49 (m, 2 
H), 7.32-7.34 (m, 2 H), 7.21-7.24 (m, 1 H), [minor 4.30-4.34 (m, 1H), major 4.15-4.19 (dddd, J 
= 6.5, 6.5, 6.5, 3.5 Hz, 1 H)], [major 3.76-3.78 (m, 1 H), minor 3.76-3.78 (m, 1 H)], 3.57-3.59 
(m, 1 H), 2.25-2.30 (m, 1 H), 2.04-2.08 (m, 2 H), 1.82-1.85 (m, 2 H), [major 1.55 (s, 3 H), minor 
1.52 (s, 3 H)]; 
13
C NMR (101 MHz, CDCl3) δ 147.7, 128.2, 126.5, 124.6, 85.3, 78.9, 65.4, 39.5, 
30.5, 27.3. HRMS m/z 193.1223 (calcd for C12H16O2+H
+
, 193.1229). 
Compound 1-19a 
The title compound was prepared according to the general cyclization 
procedure to afford a clear colourless oil (0.081 g, 42%) as a 5:1 mixture of 
diastereomers. Rf  0.39 (40% EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3)  7.31-7.38 (m, 4 
H), 7.21-7.23 (m, 1 H), [minor 4.24-4.28 (m, 1 H), major 4.11-4.15 (m, 1 H)], [major 3.76 (dd, J 
= 11.1, 3.5 Hz, 1 H), minor 3.69 (dd, J = 11.1, 3.5 Hz, 1 H), major 3.55 (dd, J = 11.7, 5.9 Hz, 1 
H), minor 3.50 (dd, J = 11.1, 5.9 Hz, 1 H)], 2.14-2.25 (m, 1 H), 2.04-2.10 (m, 1 H), 1.75-1.89 
(m, 5 H), 1.54  (brs, 1 H), [major 0.78 (t, J = 7.6 Hz, 3 H), minor 0.75 (t, J = 7.6 Hz, 3 H)]; 
13
C 
NMR (CDCl3, 101 MHz) 146.7, 146.2, 127.9, 126.3, 125.2, 125.1, 88.0, 87.8, 79.6, 78.5, 65.6, 
65.4, 37.4, 37.3, 35.7, 35.0, 27.3, 27.1, 8.7, 8.67; HRMS m/z 207.1389 (calcd for C13H18O2+H
+
, 
207.1380). 
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Compound 1-22a 
The title compound was prepared according to the general cyclization 
procedure to afford a clear colourless oil (0.035 g, 44%). Rf 0.15 (30% 
EtOAc/hexanes); 
1
H NMR (CDCl3, 400 MHz)  4.04 - 4.08 (m, 1 H), 3.67 (ddd, J = 11.2, 5.9, 
2.9 Hz, 1 H), 3.48 (ddd, J = 11.7, 5.9, 5.9 Hz, 1 H), 1.93-1.98 (m, 2 H), 1.83-1.87 (m, 3 H), 1.73-
1.82 (m, 5 H), 1.51-1.64 (m, 4 H); 
13
C NMR (CDCl3, 101 MHz)  91.9, 78.3, 65.4, 38.9, 38.1, 
36.6, 27.6, 24.0; HRMS m/z 156.1149 (calcd for C9H16O2, 156.1150). 
Compound 1-24a 
The title compound was prepared according to the general cyclization 
procedure to afford a clear colourless oil (0.064 g, 38%) as a As a 2:1 
mixture of diastereomers. Rf 0.17 (30% EtOAc/hexanes); 
1
H NMR (600 MHz, CDCl3)  5.84 
(dddd, J = 13.5, 10.6, 7.0, 7.0 Hz, 1 H), 5.00-5.02 (m, 1 H), 4.92-4.93 (m, 1 H), [minor 4.07-4.11 
(m, 1 H), major 4.02-4.06 (m, 1 H)], [major 3.67 (dd, J = 11.7, 3.5 Hz, 1 H), minor 3.64 (d, J = 
3.5 Hz, 1 H)], [major 3.47 (dd, J = 11.1, 5.3 Hz, 1 H)], 2.04-2.15 (m, 3 H), 1.89-1.98 (m, 1 H), 
1.75-1.84 (m, 2 H), 1.65-1.75 (m, 2 H), 1.53-1.65 (m, 3 H), [major 1.21 (s, 3 H), minor 1.20 (s, 3 
H)]; 
13
C NMR (CDCl3, 101 MHz) 138.9, 114.2, 114.2, 114.1, 83.5, 83.4, 79.2, 78.4, 65.3, 65.1, 
40.9, 40.1, 37.0, 36.6, 29.0, 28.9, 27.5, 27.1, 26.7, 25.6; HRMS m/z 171.1385 (calcd for 
C10H18O2+H
+
, 171.1380).  
Compound 1-25a 
The title compound was prepared according to the general cyclization 
procedure to afford a clear colourless oil (0.046 g, 19%) as a As a 5:1 
mixture of diastereomers. Rf  0.21 (30% EtOAc/hexanes); 
1
H NMR (400 
MHz, CDCl3)  7.36-7.39 (m, 2 H), 7.22-7.25 (m, 3 H), [major  4.26-4.32 (m, 1 H), minor 4.20-
4.26 (m, 1 H)], [major 3.72-3.76 (m, 1 H), minor 3.59-3.65 (m, 1 H)], 3.48-3.54 (m, 1 H), 2.25-
2.35 (m, 1 H), 2.12-2.23 (m, 1 H), 1.77-1.90 (m, 3 H), [major 1.61 (s, 3 H), minor 1.61 (s, 3 H)]; 
13
C NMR (101 MHz, CDCl3)  131.7, 131.6, 128.2, 91.9, 83.0, 80.7, 79.2, 64.9, 41.0, 40.3, 28.0, 
27.1; HRMS m/z 216.1155 (calcd for C14H16O2, 216.1150). 
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Compound 1-26a 
The title compound was prepared according to the general 
cyclization procedure to afford a clear colourless oil (0.0468 g, 
44%) as a 2:1 mixture of diastereomers. Rf  0.27 (40% EtOAc/Hexanes); 
1
H NMR (400 MHz, 
CDCl3)  7.29-7.33 (m, 2 H), 6.84-6.88 (m, 2 H), [minor 4.27 (m, 1 H), major 4.11-4.18 (m, 1 
H)], [major 3.80 (s, 3 H)], [major (ddd, J = 11.3, 6.3, 3.5 Hz, 1 H)], 3.53-3.59 (m, 1 H), 2.21-
2.28 (m, 1 H), 1.98-2.05 (m, 2 H), 1.80-1.85 (m, 2 H), [major 1.52 (s, 3 H), minor 1.50 (s, 3 H)]; 
13
C NMR (101 MHz, CDCl3) δ 158.2, 139.8, 125.8, 125.7, 113.5, 85.0, 84.7, 79.3, 78.9, 65.7, 
65.5, 55.3, 39.4, 39.3, 30.6, 27.6, 27.4; HRMS m/z 222.1256 (calcd for C13H18O3, 222.1251). 
Compound 1-27a 
The title compound was prepared according to the general cyclization 
procedure to afford a clear colourless oil (0.117 g, 45%) as a As a 2:1 
mixture of diastereomers. Rf  0.46 (40% EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3)  [minor 
4.17-4.20 (m, 1 H), major 4.09-4.13 (m, 1 H)], [minor 3.76 (dt, J = 11.2, 3.5 Hz, 1 H), major 
3.66-3.70 (m, 1 H)], [minor 3.59-3.61 (d, J = 10.6 Hz 1 H)], 3.42-3.49 (m, 5 H), 2.15-2.20 (m, 1 
H), 1.99-2.06 (m, 2 H), 1.92-1.98 (m, 2 H), 1.88-1.91 (m, 1 H), 1.76-1.82 (m, 1 H), 1.56-1.65 (m, 
2 H), [major 1.20 (s, 3 H), minor 1.15 (s, 3 H)], [minor 0.91 (s, 9 H), major 0.90 (s, 9 H)], [minor 
0.08 (s, 6 H), major 0.05 (s, 6 H)]; 
13
C NMR (101 MHz, CDCl3) 

HRMS m/z 261.1886 (calcd for C13H28O3Si+H
+
, 261.1880).  
Compound 1-30a 
The title compound was prepared according to the general 
cyclization procedure to afford a clear colourless oil (0.076 g, 35%) 
as a As a 4:1 mixture of diastereomers. Rf 0.16 (40% 
EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3)  [minor 7.68-7.69 (m, 1 H), major 7.62 (d, J = 
8.2 Hz, 2 H)], [ minor 7.54-7.55 (m, 3 H), major 7.50 (d, J = 8.8 Hz, 2 H)], [minor 4.33 (dddd, J 
= 7.0, 7.0, 7.0, 3.5 Hz, 1 H), major 4.15 (dddd, J = 7.0, 7.0, 7.0, 3.5 Hz, 1 H)], [major 3.78 (ddd, 
J = 11.7, 6.4, 3.5 Hz, 1 H), minor 3.72 (ddd, J = 11.1, 7.0, 3.5 Hz, 1 H)], 3.55-3.61 (m, 1 H), 
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2.10-2.24 (m, 3 H), 1.80-1.94 (m, 3 H), [major 1.54 (s, 3 H), minor 1.51 (s, 3 H)]; ); 
13
CNMR 
(101 MHz, CDCl3) δ 153.4, 132.2, 132.1, 125.5, 118.9, 110.4, 84.9, 84.6, 79.6, 79.4, 65.5, 65.2, 
39.4, 39.3, 30.2, 27.4, 27.3; HRMS m/z 218.1189 (calcd for C13H15NO2, 217.1103).  
Compound 1-31a 
The title compound was prepared according to the general 
cyclization procedure to afford a clear colourless oil (.129 g, 49%) as 
a As a 4:1 mixture of diastereomers. Rf  0.31 (40% EtOAc/Hexanes); 
 
1
H NMR (600 MHz, CDCl3)  7.58 (d, J = 8.2 Hz, 2 H), [minor 7.54 (d, J = 8.2 Hz, 2 H), major 
7.51 (d, J = 8.2 Hz, 2 H)], [minor 4.33 (dddd, J = 7.0, 7.0, 7.0, 3.5 Hz, 1 H), major 4.16 (dddd, J 
= 7.0, 7.0, 7.0, 3.5 Hz, 1 H)], [major, 3.78 (dd, J = 11.1, 2.9 Hz, 1 H), minor 3.71 (dd, J = 11.1, 
3.5 Hz, 1 H)],  [major 3.59 (dd, J = 11.1, 5.3 Hz, 1 H), minor 3.56 (dd, J = 11.7, 6.4 Hz, 1 H)],  
2.16-2.27 (m, 1 H), 2.04-2.13 (m, 1 H), 1.65-1.90 (m, 3 H), [major 1.55 (s, 3 H), minor 1.52 (s, 3 
H)]; 
13
C NMR (101 MHz, CDCl3) q, J  = 32.2 Hz), 125.2 (q, J = 3.8 Hz), 
125.0, 124.2 (q, J = 272.2 Hz), 85.0, 84.7, 79.6, 79.3, 65.6, 65.3, 39.4, 39.3, 30.3, 29.7, 29.4, 
27.5, 27.3; HRMS m/z 261.1110 (calcd for C13H15F3O2+H
+
, 261.1097).  
Compound 1-32 
TBSCl (0.181 g, 1.2 mmol, 1.2 eq) and imidazole (0.204 g, 3 mmol, 3 eq)  
were combined in CH2Cl2 (20 mL). Crude THF 1-19a (0.211 g, 1 mmol, 1 
eq) was introduced. After one hour half-saturated NaHCO3 (10 mL) was introduced. The layers 
were separated and the aqueous extracted with CH2Cl2 (3 x 20 mL). The combined organic layers 
were washed with brine, dried over MgSO4, filtered through Celite and concentrated under 
reduced pressure. The residue was purified by flash chromatography (8% EtOAc/Hexanes) to 
afford the title compound as a clear colourless oil (0.108 g, 34% over 2 steps) as a 3:1 mixture of 
diasteriomers; 
1
H NMR (600 MHz, CDCl3)  7.41 – 7.40 (m, 1 H), 7.38 – 7.36 (m, 2 H), 7.33 – 
7.28 (m, 2 H), 7.22 – 7.20 (m, 1 H), [minor 4.20 – 4.16 (m, 1 H), major 4.10 – 4.06 (m, 1 H)], 
3.76 – 3.72 (m, 1 H), [major 3.66 – 3.64, minor 3.57 – 3.54 (m, 1 H)],  2.17 – 2.13 (m, 1 H), 2.09 
– 2.04 (m, 1 H), 1.88 – 1.75 (m, 5 H), [major 0.93 (s, 9 H), minor 0.88 (s, 9 H)], [major 0.78 (t, J 
= 7.63 Hz, 3 H), minor 0.76 (t, J = 7.63 Hz, 3 H)],  [major 0.10 (s, 6 H), minor 0.06 (s, 3 H), 0.04 
(s, 3 H)]; 
13
C NMR (101 MHz, CDCl3)  147.4, 146.8, 127.9, 127.6,  126.1, 126.0, 125.4, 125.3, 
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87.7, 87.4, 79.9, 78.9, 65.93, 65.86, 37.7, 36.9, 35.6, 34.9, 28.3, 27.6, 25.93, 25.89, 18.3, 8.8, 8.7, 
-5.27, -5.30. HRMS m/z 261.1886 (calcd for C13H28O3Si+H
+
, 261.1880).  
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Chapter Two: Synthesis of β-Carboline Alkaloids 
2.0 Introduction  
 The development of the modified Mukaiyama cyclization procedure for tri-substituted 
bishomoallylic alcohols presented an opportunity to apply Co(nmp)2 catalyzed oxidative 
cyclizations towards the synthesis of a natural product. Such a synthesis would continue to test 
the versatility of Co(nmp)2 and demonstrate its potential to access unique target molecules. 
Chrysotricine 2-1 (Figure 2.1) was chosen as a synthetic target due to the occurrence of the 
2,5,5-substituted THF ring. The alkaloid is derived from the Chinese herb medicine Hedyotis 
chrysotricha and was first reported in 1997 as a trace alkaloid (0.0001%) isolated from the 
plant.
1
 Chrysotricine was again isolated in 1998 from H. capitellata along with several other 
notable β-Carboline alkaloids including (-)-isocyclocapitelline 2-4, (+)-cyclocapitelline 2-3 and 
isochrysotricine 2-2 (Figure 2.0).
2
 Chrysotricine was shown to inhibit the growth of HL-60 cells 
in vitro adding to its value as a synthetic target.  
 
 
Figure 2.0. β-Carboline alkaloids. 
31 
 
 
 
Chrysotricine features a 2,5,5-trans-THF core along with a tertiary alcohol at the 2 
position and a methylated β-Carboline at the 5 position. The natural product possesses an 
interesting zwitterionic structure with a positively charged quaternary nitrogen and negatively 
charged nitrogen derived from the indole nitrogen of the β-carboline. Isolation studies of the 
compound revealed that chrysotricine tautomerizes in methanol forming an equilibrium between 
2-1 and 2-2 (Scheme 2.1).2
 
 
Scheme 2.1. Tautomeric equilibrium of chrysotricine. 
 
 
 
 Biosynthetically, chrysotricine is thought be derived through the combination of a methyl 
tyrptamine derivative and trans linayl oxide 2-7, a natural product commonly found in many 
plant systems (Scheme 2.2). 2
 
 
Scheme 2.2. Proposed biosynthetic precursors to chrysotricine 
 
 
 
 Since isolation in 1997 there have been two syntheses of Chrysotricine reported in the 
literature. The first total synthesis was conducted racemically by Schollmeyer and coworkers and 
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took advantage of the proposed biosynthetic generation of Chrysotricine.
3
 Within the same year 
Liang and coworkers reported the first total synthesis of enantioenriched Chrysotricine.
4
 
Examination of these syntheses provides insight into possible strategies and pitfalls to avoid.  
2.1 Schollmeyer’s Synthesis of Chrysotricine 
 Schollmeyer and coworkers began their synthetic efforts towards chrysotricine through 
the acetylation of a commercially available diastereomeric mixture of linalyl oxides 2-7a. This 
was required in order to separate the diastereomers of the commercial mixture (Scheme 2.3). The 
separated enantiomerically pure diastereomers 2-8a and 2-8b were then converted separately into 
aldehydes 2-9 through a sequential hydroboration, oxidation of the of the pendant alkene. 
Unfortunately they found that the hydroboration/oxidation sequence caused a scrambling of 
stereochemistry resulting in a mixture of diastereomers for each of the respective products. These 
products were also found to be racemates. 
 
Scheme 2.3 Schollmeyer’s preparation of the Pictet-Spengler precursor. 
 
  
 
 Schollmeyer speculated that boroxolane 2-9a formed during the hydroboration reaction 
would destabilize the THF at the 2 and 5 position leading to ring opening forming secondary 
carbocation 2-10 or tertiary carbocation 2-11 (Scheme 2.4), thus allowing scrambling of the 
previously set stereocenters.  
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Scheme 2.4. Erosion of stereochemistry via a boroxolane intermediate. 
 
 
 
 The diastereomeric mixture of 2-9 was combined and subjected to a Pictet-Spengler 
reaction with tryptamine without isolation of the intermediate imine (Scheme 2.5). The resulting 
1-substituted-1,2,3,4-tetrahydro-β-carbolines 2-13 were acquired as a mixture of four 
diastereomeric racemates. The tetrahydro-β-carbolines were then dehydrogenated with Pd/C in 
hot o-xylene to afford β-carbolines 2-14. Removal of the acyl group was accomplished with 
K2CO3 in methanol/water to reveal the tertiary alcohol 2-15a. Finally quaternization of the β-
carboline nitrogen was accomplished with dimethyl sulfate followed by deprotonation with 2M 
KOH to afford the final product 2-1a as a mixture of enantiomers following separation. 
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Scheme 2.5. Completion of Schollmeyer’s synthesis of chrysotricine. 
 
  
 
 Schollmeyer’s synthesis produced racemic product starting from enantiomerically pure 
starting materials. The loss of stereochemistry during the hydroboration oxidation sequence of 
acylated linayl oxide was a critical problem with the synthesis.  It served as an important 
precedent demonstrating the challenges to forming the natural product using a biosynthetic 
approach.   
2.2 Liang’s Synthesis of chrysotricine. 
 Liang and coworkers chose to stay away from a biosynthetically inspired route to 
chrysotricine, instead starting with prochiral starting material. The synthesis began with the THP 
ether protection of commercially available geraniol (Scheme 2.6). Allylic oxidation of the tri-
substituted alkene then afforded primary alcohol 2-17.
5
 Protection of the newly formed alcohol 
was accomplished with benzoyl chloride followed by removal of the THP ether with PPTS to 
yield 2-18. Sharpless epoxidation of allylic alcohol 2-18 afforded epoxide 2-19 in 90% ee. 
Protection of the primary alcohol was then accomplished with benzyl bromide to afford 2-20 
followed by one pot epoxide opening and benzoyl deprotection with LiAlH4 to afford diol 2-21.  
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Scheme 2.6. Synthesis of the THF precursor. 
 
 
 A second Sharpless epoxidation of the now revealed allylic alcohol followed by ring 
closure was accomplished in one step forming the THF core of chrysotricine 2-22 with 82% de 
(scheme 2.7). Mesylation of the primary alcohol of 2-22 followed by treatment with LiAlH4 
afforded the tertiary alcohol of chrysotricine 2-24. Hydrogen gas with Pd/C was then employed 
to remove the benzyl protecting group to reveal primary alcohol 2-25. Swern oxidation of the 
primary alcohol afforded THF aldehyde 2-26 in moderate yield. 
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Scheme 2.7. Liang’s formation of the chrysotricine THF core. 
 
 
Aldehyde 2-26 converged with Schollmeyer’s racemic synthesis of chrysotricine. From 
the aldehyde Liang forms β-carboline 2-15 through a Pictet-Spengler and dehydrogenation 
sequence similar to Schollmeyer (Scheme 2.8). To complete the natural product Liang 
methylated the β-carboline nitrogen with methyl iodide followed by deprotonation with NaOH. 
Overall Liang’s synthesis provides access to chrysotricine in 16 steps (1.1% overall yield). The 
synthesis is lengthier than Schollmeyer’s and requires a number of protecting group 
manipulations but it does provide access to enantioenriched product.   
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Scheme 2.8. Completion of Liang’s synthesis of chrysotricine. 
 
 
   
 2.3 Progress Towards Chrysotricine: Synthetic Route One 
The method developed for the oxidative cyclization of tertiary bishomoallylic alcohols to 
2,5,5-trans-THFs produced THFs containing a methanol subunit at the 2 position in the resulting 
products. Chrysotricine however, has an isopropanol at the 2 position. If the THF core of 
Chrysotricine and the isopropanol unit could be formed simultaneously through a Mukaiyama 
cyclization it would provide access to an advanced Chrysotricine intermediate in very short 
order. Such a transformation would require cyclization of a bishomoallylic alcohol containing a 
tri-substituted alkene. Cyclizations with this class of tertiary pentenol had not yet been attempted 
with the Mukaiyama cyclization protocol and thus it was advantageous to try to extend the 
methodology further to this class of tertiary bishomoallylic alcohols.  
 Retrosynthetically, chrysotricine could be arrived at through a Pictet-Spengler reaction 
between tryptamine and THF aldehyde 2-26 (Scheme 2.9) in a similar manner to that described 
by Schollmeyer and Liang. This would be followed by oxidation of the resulting tetrahydro-β-
carboline, methylation of the carboline nitrogen and finally deprotonation of the indole nitrogen 
to give the zwitterionic natural product. The THF aldehyde 2-26 would be arrived at through an 
oxidative cyclization of protected pentenol 2-29 followed by deprotection and oxidation of the 
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primary alcohol. Ultimately the pentenol would come from the opening of enantioenriched 
epoxide 2-30 with the appropriate prenyl nucleophile 2-31. 
 
Scheme 2.9. Retrosynthetic analysis of Chrysotricine. 
 
 
 
 Forward synthetic efforts towards Chrysotricine began with protection of Methyl-3-
buten-1-ol as benzyl protected alcohol 2-33 in excellent yield (Scheme 2.10).
6 
 Epoxidation of 2-
33 was readily carried out with mCPBA to give racemic epoxide 2-30a. With the epoxide in 
hand the next step was to conduct and epoxide opening in order to access substituted pentenol 2-
29a for use in the key core forming cyclization step. When epoxide 2-30a was introduced to 
prenyl cuprate 2-34 formation of tertiary pentenol 2-29a was accomplished in 26% yield with 
54% recovery of starting material.
7
 Subsequent attempts to modify the reactions conditions of 
this addition were unsuccessful in increasing the yield. Monitoring of the reaction mixtures by 
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TLC indicated that the reaction failed to go to completion, leaving significant quantities of 
epoxide unreacted. Increasing the amount of copper(I)iodide in an attempt to force the reaction  
to completion resulted in unwanted byproducts and the use of prenyl magnesium chloride alone 
was ineffective. The epoxide was prone to opening by chloride at elevated temperatures making 
reproducibility of the method challenging.  
 
Scheme 2.10. Route one forward synthetic efforts. 
 
 
 
Having obtained pentenol 2-29a in modest amount, an attempt was made at cyclizing the 
substrate in order to form the core of chrysotricine. Unfortunately the conditions established for 
the cyclization of tertiary pentenols onto mono-substituted alkenes were unsuccessful when 
applied to tri-substituted alkene 2-29a yielding only recovered starting material. 
2.4 Development of a Model System 
 After determining that alkenol 2-29a could not be cyclized under the Mukaiyama 
cyclization procedure, we chose to develop a simpler model substrate in order to test the overall 
viability of cyclizing tertiary alkenols bearing tri-substituted alkenes with the Co(nmp)2 catalyst. 
2,6-dimethylhept-5-en-2-ol 2-36 was chosen as it represents the simplest such substrate. 
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Synthesis of the pentenol was carried out by addition of methyl magnesium bromide to 
commercially available 6-methylhept-5-en-2-one 2-35 in 79% yield. 
With the cyclization substrate in hand efforts were made to cyclize the compound under 
modified Mukaiyama conditions (Table 2.0). Following the short reaction screening it became 
clear that simple modifications of the reaction conditions would not permit the formation of the 
product. Increasing the temperature (entry 1), changing the solvent and altering the catalyst 
loading (entries 2 and 3) and the use of high pressure (entry 4) did not yield any product. Further 
experimentation is needed to establish conditions suitable for the cyclization, however it may be 
that the Co(nmp)2 catalyst is simply not suited to such substrates. 
 
Table 2.0. Cyclization of a model substrate. 
 
 
Entry Cat Solvent Temp Product 
1 17.5 sBuOH 100 N/A 
2 10 EtOH 75 N/A 
3 20 EtOH 75 N/A 
4 17.5 CH2Cl2 rt 
150,000 psi 
N/A 
 
Hartung has demonstrated the potential for secondary alcohols bearing tri-substituted 
alkenes to cyclize using a bis[3-trifluoroacetylcampherato(−1)]cobalt(II) complex however with 
low yield, poor selectivity and considerable byproduct formation.
8
 When Co(nmp)2 was applied 
to a secondary pentenol, 6-methylhept-5-en-2-ol however, the reaction failed to yield any 
cyclized product (Scheme 2.11.) 
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Scheme 2.11.  Attempted cyclization of 6-methylhept-5-en-2-ol. 
 
 
 While it is still unclear why this class of substrate is as yet incompatible with the 
Co(nmp)2 catalyst it may be speculated that both steric and electronic factors are limiting the 
ability of Co(nmp)2 to successfully catalyze the cyclization.   
2.5 Revised Synthetic Route to Chrysotricine: Route Two 
 After having determined that cyclizations of tertiary pentenols bearing tri-substituted 
alkenes was not achievable under our established cyclization conditions we chose to revise our 
synthetic route to chrysotricine. Retrosynthetically, (scheme 2.12), THF aldehyde 2-26 would 
arise from THF alcohol 2-40 through an oxidation of the secondary alcohol followed by addition 
of a methyl nucleophile. Deprotection of the primary alcohol and oxidation would then afford the 
aldehyde. 
 
Scheme 2.12. Revised retrosynthesis. 
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THF alcohol 2-40 would come from cyclization of pentenol 2-41 which in turn would 
arise from epoxide 2-42 following cleavage of the alkene bond through ozonolysis, Wittig 
olefination and epoxide opening. The protected epoxide 2-42 would be arrived at through the 
elaboration of commercially available geraniol via a Sharpless asymmetric epoxidation and 
protection of the primary alcohol.   
This synthetic route would employ yet another untested Mukaiyama cyclization substrate, 
a bishomoallylic tertiary alcohol possessing a di-substituted alkene. Such a cyclization would 
again be advantageous to extend the previously developed methodology to a new class of 
substrates. In addition the ability to conduct a Sharpless asymmetric epoxidation on geraniol 
would simplify the production of enantiomerically enriched material at an early stage.  
 
Scheme 2.13. Route two forward synthetic efforts. 
 
 
 Sharpless epoxidation of geraniol was carried out readily to yield enantioenriched 
epoxide 2-43 in 97% yield and 86% ee as determined through Mosher’s ester analysis (Scheme 
2.13).
9
 Protection of epoxide 2-43 as the TBS ether was accomplished in 97% yield. After 
acquiring the primary alcohol protected epoxy geraniol 2-42 the tri-substituted olefin was 
cleaved via ozonolysis followed by a reductive workup with dimethyl sulfide to yield epoxy 
aldehyde 2-44. Wittig olefination of the aldehyde then provided access to alkene 2-45. With 
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alkene 2-45 in hand an epoxide opening was all that remained in order to access key cyclization 
precursor 2-41. Epoxide opening was carried out with LiAlH4 in refluxing THF. The opened 
product was acquired however the opening occurred along with loss of the TBS protecting group 
providing diol 2-46. The loss of the TBS group at this stage was inconsequential as it could be 
selectively re-protected at a later stage.  
 Pentenol 2-46 was then subjected to the standard oxidative cyclization conditions. 
Gratifyingly, the cyclization was successful producing THF 2-47 in 19% yield as a complex 
mixture of diastereomers. 
 The formation of THF 2-47 presents a new substrate class for this type of Mukaiyama 
cyclization with the Co(nmp)2 catalyst however further optimization is required for the method 
to be effective within the synthetic route to chrysotricine. Given the low yield of the cyclization 
product this synthetic route was abandoned in favor of higher yielding alternatives.  
2.6 Synthetic Route Three 
 The Mukaiyama cyclization of tertiary pentenols bearing di and tri substituted alkenes 
proved to be an ineffective strategy towards the synthesis of chrysotricine. As a result a third 
synthetic strategy towards chrysotricine was developed (Scheme 2.14). Similarly to route two, 
route three would see THF aldehyde 2-26 arising from tertiary alcohol 2-48 following 
deprotection of the primary alcohol and oxidation. 
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Scheme 2.14. Route three retrosynthetic analysis. 
 
 
 
 The tertiary alcohol would arise from THF methanol 2-49 via a stepwise oxidation of the 
free alcohol and double methyl nucleophile addition. THF methanol 2-49 would arise from a 
Mukaiyama oxidative cyclization of key cyclization substrate 2-50, a tertiary pentenol bearing a 
monosubstituted alkene. As cyclizations of these substrates had previously been established it 
was thought that use of the monosubstituted alkene would provide for greater yields and a more 
effective synthetic strategy. The pentenol would come from protected hydroxy alkene 2-51 
following ozonolysis of the alkene and Wittig olefination of the resulting aldehyde. Hydroxy 
alkene 2-51 would arise from an opening of 2,3-epoxy-geraniol followed by selective protection 
of the primary alcohol.  
 Forward synthetic progress began again with previously synthesized 2,3-epoxy geraniol 
2-43 (Scheme 2.15). Opening of 2,3-epoxy-geraniol followed by selective TBS protection of the 
primary alcohol was accomplished in 89% yield over two steps. Epoxide opening was conducted 
at an earlier stage in this synthetic route in order to avoid loss of the silyl protecting group as 
previously observed. Ozonolysis of 2-51 followed by reductive workup provided a complex 
product mixture most likely due to formation of a hemiacetal through addition of the tertiary 
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alcohol to the newly formed aldehyde. Purification of this material proved challenging and thus 
crude material was transferred directly onward to the next step. Wittig olefination of the crude 
mixture yielded pentenol 2-50 in a low 7% yield over two steps. 
 
Scheme 2.15. Route three forward synthetic efforts. 
 
 
 Key cyclization substrate 2-50 was subjected to oxidative cyclization under the modified 
Mukaiyama procedure. Gratifyingly after exposing the pentenol to pre-oxidized Co(nmp)2 
(17.5%) for 16 hours in sec-butanol at 80 °C, THF methanol was acquired in 34% yield (39% 
BRSM) as a 3:1 mixture of diastereomers. The yield of this product was along the lines of other 
THFs prepared via this method. We hoped that further optimization of this reaction would enable 
us to increase the yield slightly.  
 Having exhausted a significant amount of material in efforts to obtain THF methanol 2-
49 production of larger quantities of starting materials was required. A significant loss of 
material had occurred during the ozonolysis and Wittig reaction sequence. At this stage we chose 
to return to a previous strategy of late stage epoxide opening in order to avoid the complex 
mixture seen following ozonolysis of tertiary alcohol 2-51. This strategy would be more effective 
but only if loss of protecting groups could be avoided during epoxide opening.  
 To circumvent this problem, the more robust triisopropylsilyl (TIPS) protecting group 
was chosen to mask the primary alcohol of geraniol. Epoxide 2-53 was acquired in a three step 
TIPS protection, ozonolysis and Wittig methylation sequence in 66% overall yield. 
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Unfortunately treatment of the epoxide with LiAlH4 did not produce opened product with 
retention of the silyl protecting group as desired. Monitoring of the reaction mixture by TLC 
revealed slow and incomplete conversion to diol 2-55 with loss of the TIPS protecting group 
(Scheme 2.16).  
 
Scheme 2.16. Attempted opening of TIPS protected 2,3-epoxy-geraniol. 
 
  
 
2.7 Synthetic Route Four 
Undeterred by the setbacks of the previous synthetic efforts, we compiled all of the 
successful steps from the previous synthetic routes in order to develop a route with the most 
effective steps as possible. Towards that end, a fourth synthetic route to chrysotricine was 
established. In this approach late stage epoxide opening along with loss of silyl protecting group 
would be followed by selective re-protection of the primary alcohol of 2-55 (Scheme 2.17).  
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Scheme 2.17. Chrysotricine synthetic route four. 
 
 
 
Starting from aldehyde 2-44, Wittig olefination with the ylide of 
methytriphenylphosphonium bromide yielded alkene 2-56. Opening with LiAlH4 in refluxing 
THF provided diol 2-55 in 86% yield. The primary alcohol was then selectively re-protected as 
the TBS ether in 86% yield providing cyclization substrate 2-50. With the cyclization substrate 
once again in hand cyclization was carried out to provide protected THF methanol 2-49 this time 
in 43% yield (52% BRSM) as a 3:1 mixture of diastereomers and improved yield over the 
previous cyclization.  
Protected THF methanol 2-49 was carried forward by oxidation of the primary alcohol to 
its corresponding carboxylic acid with a TEMPO/BAIB oxidation system (Scheme 2.18).
10
 
Methylation of the resulting crude carboxylic acid was accomplished with 
trimethylsilyldiazomethane to provide ester 2-57 over two steps in 88% yield.
11
 Tertiary alcohol 
2-48 was then acquired through a sequential double methyl Grignard addition and overall yield 
of 89%. Finally, removal of the TBS protecting group was accomplished using TBAF to provide 
THF alcohol 2-25 in 53% yield. THF alcohol 2-25, constitutes a formal synthesis of 
chrysotricine based on the total synthesis of Liang and coworkers. 
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Scheme 2.18. Completion of formal synthesis. 
 
 
 With THF diol 2-25 in hand only five synthetic steps remained to the completion of 
chrysotricine. Before embarking on the remaining forward synthetic steps however we chose to 
go back and optimize the route thus far in order to create a more effective synthesis to carry 
through large quantities of material. Despite having formed the formal synthetic product, several 
of the steps in getting to the product had been low yielding; for example the Wittig olefination 
was challenging on large scale in terms of purification given the difficulty in removal of the 
significant quantity of phosphine oxide byproduct formed. Additionally, ozonolysis products 
were difficult to reproduce with consistent yield.  
 Our optimization efforts began with the ozonolysis/Wittig olefination sequence with the 
goal of replacing the two steps with a one-step conversion of protected 2,3-epoxy geraniol 2-43 
directly to alkene 2-58. The most direct method for such a transformation would be a cross 
metathesis of 2-43 with ethylene gas to effectively convert the tri-substituted alkene of geraniol 
to the desired mono-substituted alkene (Scheme 2.19).  
 
Scheme 2.19. Direct conversion of 2-43 to 2-58. 
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  Olefin cross metathesis has seen a significant increase in use for synthetic 
transformations since the development of more active catalyst systems such as the Grubb’s and 
Hoveyda-Grubb’s type catalysts (Figure 2.1). Despite this its application is still less common 
than other olefin metathesis methods such as ring opening metathesis polymerization (ROMP) 
and ring closing metathesis (RCM).
12
 This can be attributed to several factors such as lower 
catalyst activity towards cross metathesis as compared to ROMP or RCM, lower product 
selectivity for the cross metathesis product (loss of yields due to homodimerization and 
secondary metathesis products), and poorer selectivity for stereochemistry in the newly formed 
olefin.  
 
 
 
Figure 2.1. Cross metathesis catalysts.  
 
 With respect to cross metathesis of substrate 2-43 only one alkene is present for 
metathesis and the stereochemistry of the resulting product is not an issue. The anticipated 
difficulty with the transformation was with the activity of the catalyst towards the hindered tri-
substituted alkene and the possible de-activation of the catalyst by the ethylene gas reagent. 
 Our work towards this transformation began with alkene 2-43 as the cross metathesis 
partner with ethylene gas (Table 2.1). Several metathesis conditions were probed including the 
use of a high pressure Parr reactor, however all attempts failed to produce all but trace amounts 
of product leaving starting material mostly untouched (entries 1-2). Undeterred we switched 
unprotected alcohol 2-43 for protected alcohol 2-42.  
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 Gratifyingly after bubbling ethylene gas through a solution of alkene 2-42 with a 5% 
catalyst loading of Grubbs second generation catalyst and heating the solution to reflux the 
desired cross metathesis product was acquired. The reaction however, failed to go to completion 
and a complex mixture of dimer product was also present. Separation of the dimer was possible 
via column chromatography; however the starting material and product were acquired as an 
inseparable mixture.  
 
Table 2.1. Optimization of cross metathesis. 
 
 
 
 
Entry R Catalyst Reaction 
Time 
(h) 
Catalyst 
Loading 
(%) 
Concentration 
[mmol]
a
 
Product 
Ratio 
A:B:C 
1 H Grubbs II 24 5 0.33
b
 1:>16:0 
2 H Grubbs II 24 5 0.06
c
 1:>10:0 
3 TBS Grubbs II 24 5 0.14 1:1:0.4 
4 TBS Grubbs II 2 5 0.05 1:1:1.5 
5 TBS Grubbs II 50 min 5 0.016 1:1:0.1 
6 TBS Grubbs II 1.5 5 0.008 2:1:0 
7 TBS Grubbs II 3 5 0.008 3:1:0 
8 TBS Grubbs I 24 5 0.008 - 
9 TBS Grubbs II 3 1 0.008 1:1:0 
10 TBS Grubbs II 24 2 0.008 2:1:0 
11 TBS Grubbs II 24 2 0.008
c
 1:13:0 
12 TBS Hoveyda-
Grubbs II 
24 3 0.008 2:1:0.3 
13 TBS Grubbs II 24 3 0.008 2:1:0 
14 TBS Grubbs II 24 3 0.014
d
 5:1:0.2 
15 TBS Grubbs II 24 3 0.014
d
 3:1:0 
a
 All reactions run at 0.5 mmol unless otherwise noted. 
b 1 mmol scale 
c Parr reactor, 80 psi ethylene gas 
d 3.5 mmol scale 
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 With the initial success of the cross metathesis reaction we looked for new conditions that 
would suppress dimer formation and yet force the reaction to completion. Increasing the dilution 
to 0.008M was effective at suppressing formation of the dimer product (entries 3-7). Lowering 
the catalyst loading to 1% and 2% yielded lower levels of conversion (entries 9-10). A 3% 
catalyst loading proved to be the most effective in terms of conversion and economy producing 
consistent and scalable result (entries 13-15). Use of the high pressure Parr reactor produced only 
a minor amount of product (entry 11). The Hoveyda-Grubbs second generation catalyst provided 
product albeit with a greater percentage of dimer side product (entry 12). Grubb’s first 
generation catalyst failed to catalyze the reaction at all providing only starting material (entry 8). 
The failure of Grubb’s I to catalyze the reaction was disappointing although not unexpected. The 
catalyst is less active than its second generation counterparts however from an operational 
standpoint its ineffectiveness was a setback as it is notably cheaper.  
 Having optimized the conditions for cross metathesis of 2-42 the issue of purification of 
the crude material became the next synthetic obstacle due to the starting material and product 
being completely inseparable through column chromatography. An alternative method had to be 
developed for their separation. We overcame this obstacle via an oxidative work up with 
mCPBA. In the presence of a mixture of alkenes with differing substitutions, mCPBA will 
selectively epoxidize the more electron rich alkenes first. In the case of the crude epoxide 
mixture, tri-substituted alkene starting material 2-42 and mono substituted alkene product 2-56, 
the more electron rich 2-42 would be epoxidized first. 
 We believed that selective epoxidation of 2-42 within the crude reaction mixture would 
allow for it to be separated from the desired mono-substituted alkene product via column 
chromatography. Gratifyingly, when the crude reaction mixture was treated with mCPBA the 
desired alkene product was found to be separable from the epoxidized starting material allowing 
for isolation of 2-56 through column chromatography.  
 It should be noted that an attempt was made to carry the inseparable cross metathesis 
product/starting material mixture through an epoxide opening and oxidative cyclization 
sequence. Opening of the epoxide was possible but separation of the two opened products was 
still not attainable. Cyclization of the opened mixture produced substantially reduced yields of 
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THF product 2-49 most likely due to interference of the tri-substituted alkene contaminant with 
the Co(nmp)2 catalyst.  
 Overall, employing a 3% catalyst loading of Grubbs second generation catalyst in with 
alkene 2-42 and ethylene gas in CH2Cl2 followed by workup with mCPBA gave access to the 
cross metathesis product 2-56 in 54% yield (Scheme 2.20). This approach shows a significant 
improvement over the previous ozonolysis/Wittig olefination sequence. The cross metathesis 
procedure produced yields comparable to the two step sequence, was easier to employ, and 
provided quicker and more direct access to the desired product.   
 
Scheme 2.20. Cross metathesis of 2-42 with ethylene gas. 
 
 
 
Having obtained a direct route to epoxide 2-56 we now focused our attention on the issue 
of epoxide opening and concurrent loss of silyl protecting group. Thankfully, with a short 
reactant screening it was discovered that Lithium tri-sec-butylborohydride (L-selectride) was 
able to open the epoxide without loss of the silyl protecting group and with higher overall yields 
(Scheme 2.21).  
 
Scheme 2.21. Epoxide opening with L-selectride. 
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The optimization of several of the synthetic steps towards chrysotricine constituted an 
overall optimized route towards the natural product (Scheme 2.22). From geraniol, Sharpless 
epoxidation provided access to epoxide 2-43. TBS protection was carried out in excellent yield 
affording protected epoxy geraniol 2-42. Cross metathesis of 2-42 yielded alkene 2-56 in 54% 
yield in one step compared to a yield of 67% when the two step ozonolysis/Wittig sequence was 
employed. Opening of 2-56 was accomplished in 91% yield with L-selectride with retention of 
the silyl protecting group as compared to a yield of 86% over two steps when 2-56 was opened 
with LiAlH4 with loss of the protecting group and then re-protected. Finally, oxidative 
cyclization of 2-50 provided THF methanol 2-49 in 43% yield and 3:1 dr. Overall the optimized 
route has five steps to key cyclization product 2-49 as compared to seven steps in the previous 
synthetic route.  
 
Scheme 2.22. Optimized synthetic route. 
 
 
 
Further optimization was carried out when it was discovered that removal of the TBS 
protecting group of 2-48 could be accomplished in higher yield (92% vs 53%) when camphor 
sulfonic acid was employed in a catalytic amount in methanol/THF (Scheme 2.23).  
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Scheme 2.23. TBS deprotection with 10-CSA. 
 
 
 
To complete the total synthesis of chrysotricine, the primary alcohol of 2-25 was oxidized 
under Parikh-Doering conditions to afford THF aldehyde 2-26 in 76% yield (Scheme 2.24).
13
 
When TFA was introduced to a mixture of tryptamine and THF aldehyde 2-26 tetrahydro-β-
carboline 2-27 was acquired as a complex mixture of diastereomers along with a significant 
amount of byproducts. Separation of the Pictet-Spengler product followed by dehydrogenation 
with Pd/C afforded the β-carboline product 2-15 in 17% yield over two steps as a 1.5:1 mixture 
of diastereomers.
14
  
 
Scheme 2.24. Completion of cyclocapitelline. 
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The synthesis of β-carboline product 2-15 constitutes a total synthesis of the natural 
product cyclocapitelline 2-3. When comparing the NMR spectra of the 1.5:1 mixture of 
diastereomers to the reported spectra of cyclocapitelline it became evident that one set of 
diastereomeric peaks corresponded to cyclocapitelline with its trans stereochemistry at the 2 and 
5 positions of the THF.2 The peaks from the other diastereomer were found to correspond to 
isocyclocapitelline the cis diastereomer of cyclocapitelline. This spectroscopic evidence confirms 
that both cis and trans 2,5,5-THFs were formed during the oxidative cyclization reaction which 
formed the molecules THF core 2-49. The major diastereomer corresponded to the trans 
diastereomer, cyclocapitelline, which confirms the oxidative cyclizations propensity for the 
formation of trans stereochemistry at the 2 and 5 positions of the THF products.  
Following the procedure of Liang, an attempt was made to methylate the nitrogen of the 
β-carboline with methyl iodide followed by deprotonation to form chrysotricine. Analysis of the 
crude material after the deprotonation step indicated that chrysotricine may have been present 
however no product could be isolated through flash chromatography. Unmethylated starting 
material was recovered, but interestingly the dr had been eroded from 1.5:1 to 1:1. This may 
indicate that during the methylation reaction one diastereomer (the trans) is preferentially 
methylated over the other.  Due to a lack of advanced material and lack of time synthetic efforts 
were ceased at this point.  
2.8 Conclusion and Future Work 
 This chapter has outlined the synthetic work conducted towards the synthesis of β-carboline 
alkaloids cyclocapitelline and chrysotricine. A total synthesis of cyclocapitelline was completed 
providing the product as a 1.5:1 mixture of diastereomers. The formal synthesis of chrysotricine 
was also completed based on the total synthesis of Liang and coworkers. 
 The THF core of the natural products was formed through a Mukaiyama aerobic oxidative 
cyclization of a tertiary bishomoallylic alcohol with the Co(nmp)2 catalyst. The formation of the 
core demonstrates the potential for Co(nmp)2 to be employed in the synthesis of complex natural 
products.  
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 Future work would see the completion of chrysotricine through a final methylation and 
deprotonation sequence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
 
 
2.9 Experimental 
2.9.1 General Experimental Details 
All reactions were conducted under Argon atmosphere unless otherwise indicated. All 
glassware was oven dried and cooled in a desiccator prior to use. Solvents and reagents were 
purified using standard methods.
15
 All reactions were stirred with a magnetic stir bar. 
Dichloromethane, diethyl ether, and tetrahydrofuran were purified by passing solvents through 
activated alumina columns. Isopropyl alcohol was used as obtained from Caledon Laboratory 
Chemicals. All other chemicals were reagent grade and used as obtained from commercial 
sources unless otherwise noted. The progress of reactions were monitored by thin layer 
chromatography (TLC) performed on F254 silica gel plates. The plates were visualized by 
staining with potassium permanganate or ceric ammonium molybdate (CAM). Column 
chromatography was performed with Silica Flash P60 60 Å silica gel from Silicycle according to 
the Still method.
16
 
 
1
H and 
13
C NMR were acquired on 400 and 600 MHz spectrometers in deuterated 
chloroform. 
1
H NMR were referenced to residual chloroform at  7.26 ppm and the center peak 
of the triplet at  77(t) ppm for 13C NMR. When peak multiplicities are given, the following 
abbreviations are used: s, singlet; d, doublet; dd, doublet of doublets; ddd, doublet of doublet of 
doublets; ddt, doublet of doublet of triplets; t, triplet; q, quartet; m, multiplet; br, broad; app, 
apparent. EI mass spectra were obtained on a Finnigan MAT 8200 spectrometer at an ionizing 
voltage of 70 eV.  
2.9.2 Experimental Details 
Compound 2-33 and 2-43 were prepared according to a literature procedures.6
,9 
Compound 2-30a 
To a flask containing Benzyl protected alcohol 2-33 (0.52 g, 3 mmol, 1.0 equiv) 
in 10 mL CH2Cl2 was added mCPBA (70%, 0.81 g, 3.3 mmol, 1.1 equiv) 
resulting in a pale yellow solution. The reaction mixture was allowed to stir for 2.5 hr. The 
resulting opaque white solution was quenched with saturated K2CO3 (20 mL). The layers were 
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separated and aqueous extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were 
washed with NaHCO3, brine, dried over MgSO4, filtered through Celite then concentrated under 
reduced pressure. The resulting crude oil was purified by flash chromatography (15% 
EtOAc/hexanes) to yield the title compound as a clear colourless oil (96%, 0.5540 g). Rf  0.5 
(25% EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  7.37 – 7.27 (m, 5 H), 4.50 (s, 2 H), 3.82 – 
3.52 (m, 2 H), 2.70 (d, J = 4.7 Hz, 1 H), 2.59 (d, J = 5.1 Hz, 1 H), 1.98 – 1.91 (m, 2 H), 1.34 (s, 
3 H); 
13
C
 
NMR (101 MHz, CDCl3)  138.2, 128.4, 127.6, 73.0, 66.6, 55.5, 54.0, 36.6, 21.5. 
HRMS m/z 192.1158 (calcd for C12H16O2, 192.1150).  
Compound 2-29a 
Prenyl chloride (0.23 mL, 2 mmol, 2 eq) was introduced to a 
suspension of Mg (0.05g, 2.05 mmol, 2.05 eq) in THF (2 mL). After 
30 min the resulting Grignard reagent was transferred to a suspension of CuI (0.038g, 0.2 mmol, 
0.2 eq) in THF (3 mL) at -78 °C. The solution was stirred for 20 minutes before introducing 
benzyl protected epoxide 2-30a (0.19 g, 1 mmol, 1 eq) in THF (0.7 mL). The resulting solution 
was stirred for 10 min at -78 °C following which the cooling bath was removed. After 1 h excess 
cuprate was quenched with the addition of saturated NH4Cl (10 mL). The resulting solution was 
filtered through Celite and the layers separated. The aqueous was extracted with CH2Cl2 (3 x 20 
mL). The combined organic layers were washed with brine, dried over MgSO4, filtered through 
Celite and concentrated under reduced pressure. The residue was purified by flash 
chromatography (10 % EtOAc/hexanes) to yield the title compound as a clear colourless oil 
(0.068 g, 26%). 
1
H NMR (400 MHz, CDCl3)  7.37-7.27 (m, 5 H), 5.13 – 5.09 (m, 1 H), 4.52 (s, 
2 H), 3.74 – 3.70 (m, 2 H), 2.09 – 1.98 (m, 2 H), 1.89 – 1.72 (m, 2 H), 1.68 (s, 3 H), 1.61 (s, 3 
H), 1.56 – 1.43 (m, 2 H), 1.19 (s, 3 H); 13C NMR (101 MHz, CDCl3)  137.8, 128.4, 127.7, 
124.5, 73.4, 72.3, 67.5, 42.3, 39.8, 26.6, 25.7, 22.7, 17.6. HRMS m/z 263.2001 (calcd for 
C17H26O2+H
+
, 263.2006). 
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Compound 2-36 
 To a solution of 2,6-dimethylhept-5-en-2-ol (1.89 g, 15 mmol, 1 eq) in ether  
(50 mL) was added dropwise over 10 min, 3M methylmagnesium bromide (7.5 
mL, 22.5 mmol, 1.5 eq). After 45 min excess Grignard reagent was quenched through addition of 
half-saturated NH4Cl (20 mL). The layers were separated and the aqueous extracted with ether (3 
x 20 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered 
through Celite and then concentrated under reduced pressure. The resulting crude material was 
purified by flash chromatography (10% EtOAc/Hexanes) to afford the title compound as a 
volatile clear colourless oil with a strong fruity fragrance (1.69 g, 79 %). Rf  0.36 (20% 
EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3) δ 5.12-5.15 (m, 1 H), 2.06 (dddd, J = 7.0, 7.0, 
7.0, 7.0 Hz, 2 H), 1.69 (s, 3 H), 1.63 (s, 3 H), 1.51 (ddd, J = 5.9, 8.8 Hz, 2 H), 1.30 (s, 1 H), 1.22 
(s, 6 H); 
13
C NMR (100 MHz, CDCl3) δ 131.7, 124.4, 71.0, 43.6, 29.2, 25.7, 23.1, 17.6; HRMS 
m/z 143.1437 (calcd for C9H18O+H
+
, 143.1430). 
Compound 2-42 
 Epoxide 2-43 (4.0 g, 23 mmol, 1 eq) was taken up in CH2Cl2 (100 
mL). To the resulting solution were added imidazole (3.4 g, 50 
mmol, 2.2 eq), TBSCl (3.5 g, 23 mmol, 1 eq), and DMAP (0.28 g, 2.3 mmol, 0.1 eq). The 
reaction was monitored by TLC for completion. On depletion of the starting material half-
saturated NaHCO3 (50 mL) was added. The layers were separated and the aqueous extracted 
with CH2Cl2 (3 x 50 mL). The combined organic layers were washed with brine, dried over 
MgSO4, filtered through Celite and then concentrated under reduced pressure. The resulting 
crude material was purified by flash chromatography (2% EtOAc/Hexanes-10% 
EtOAc/Hexanes) to afford the title compound as a clear colourless oil (6.32 g, 97%). Rf  0.69 
(10% EtOAc/Hexanes); 
1
H NMR (400 MHz, CDCl3) δ 5.07-5.12 (m, 1 H), 3.69-3.77 (m, 2 H), 
2.90 (t, J = 5.3 Hz, 1 H), 2.04-2.11 (m, 2 H), 1.63-1.70 (m, 1 H), 1.68 (d, J = 1.2 Hz, 3 H), 1.60 
(s, 3 H), 1.41-1.49 (m, 1 H), 1.26 (s, 3 H), 0.91 (s, 9 H), 0.09 (s, 3 H), 0.08 (s, 3 H); 
13
C NMR 
(100 MHz, CDCl3) δ 132.0, 123.5, 63.2, 62.3, 60.5, 38.6, 25.9, 25.7, 23.8, 18.3, 17.6, 16.7, -5.2, 
-5.3; HRMS m/z 285.2243 (calcd for C16H32O2Si+H
+
, 285.2244). 
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Compound 2-44 
 Protected epoxide 2-42 (0.285 g, 1 mmol, 1 eq) was taken up in 
CH2Cl2 (20 mL) and cooled to -78 °C. Ozone was bubbled through the 
solution (open to atmosphere) until excess blue ozone could be seen. The reaction was then 
placed under Argon (balloon) and dimethyl sulfide (0.22 mL, 3 mmol, 3 eq) was introduced. The 
resulting solution was allowed to warm to room temperature following which it was poured into 
water (30 mL). The layers were separated and the aqueous extracted with CH2Cl2 (3 x 15 mL). 
The combined organic layers were dried over MgSO4, filtered through Celite and concentrated 
under reduced pressure. The resulting crude material was purified by flash chromatography (5% 
EtOAc/Hexanes-10% EtOAc/Hexanes) to afford the title compound as a clear colourless oil 
(0.696 g, 66 %). Rf  0.39 (20% EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3) δ 9.78 (s, 1 H), 
3.73 (d, J = 5.3 Hz, 2 H), 2.91 (t, J = 5.3 Hz, 1 H), 2.52-2.54 (m, 2 H), 1.86-1.97 (m, 2 H), 1.28 
(s, 3 H), 0.90 (s, 9 H), 0.09 (s, 3 H), 0.08 (s, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 201.2, 62.8, 
62.0, 59.5, 39.1, 30.1, 25.9, 18.3, 17.0, -5.2, -5.4; HRMS m/z 259.1729 (calcd for 
C13H26O3Si+H
+
, 259.1724). 
Compound 2-45 
 Ethyltriphenylphosphonium bromide (1.86 g, 5 mmol, 5 eq) was 
dissolved in toluene (30 mL) and cooled to 0 °C. To the resulting 
solution was added KOtBu (0.56 g, 5 mmol, 5 eq). The resulting ylide 
was allowed to stir for 30 min before cooling to -78 °C. Aldehyde 2-44 in 10 mL toluene was 
then introduced and the reaction monitored by TLC for completion. Following depletion of the 
starting material water (30 mL) was introduced. The layers were separated and the aqueous 
extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over MgSO4, 
filtered through Celite and concentrated under reduced pressure. The resulting crude material 
was purified by flash chromatography (5% EtOAc/Hexanes) to afford the title compound as a 
clear colourless oil (0.228 g, 84%). Rf  0.73 (20% EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3) 
δ 5.43-5.49 (m, 1 H), 5.35-5.39 (m, 1 H), .37 (dd, J = 5.3, 2.4 Hz, 2 H), 2.91 (t, J = 5.3 Hz, 1 H), 
2.10-2.20 (m, 2 H), 1.70 (ddd, J = 14.1, 8.8, 6.5 Hz, 1 H), 1.61-1.62 (m, 3 H), 1.48 (ddd, J = 
13.5, 9.4, 6.5 Hz, 1 H), 1.28 (s, 3 H), 0.91 (s, 3 H), 0.09 (s, 3 H), 0.08 (s, 3 H); 
13
C NMR (100 
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MHz, CDCl3) δ 129.4, 124.4, 63.2, 62.2, 60.4, 38.3, 25.9, 22.6, 18.3, 16.7, 12.7, -5.4; HRMS m/z 
271.2090 (calcd for C15H30O2Si+H
+
, 271.2088). 
Compound 2-46 
A suspension of LiAlH4 (0.045 g, 1.2 mmol, 1.5 eq) in THF (5 mL) was 
cooled to 0 °C. To the suspension was added Alkene 2-45 (0.214 g, 0.8 
mmol, 1 eq) in 6 mL THF. The ice bath was then removed and the reaction heated to reflux and 
left to stir overnight. The reaction mixture was allowed to cool to room temperature and then 
excess LiAlH4 was quenched by slow addition of water (10 mL). The layers were separated and 
the aqueous extracted with ether (3 x 10 mL). The combined organic layers were dried over 
MgSO4, filtered through Celite and then concentrated under reduced pressure. The resulting 
crude material was purified by flash chromatography (70 % EtOAc/Hexanes) to afford the title 
compound as a clear colourless oil (0.110 g, 87%). Rf  0.26 (70% EtOAc/Hexanes); 
1
H NMR 
(400 MHz, CDCl3) δ 5.37-5.51 (m, 2 H), 3.84-3.95 (m, 2 H), 2.62 (m, 1 H), 2.31 (m, 1 H), 2.08-
2.16 (m, 2 H), 1.82 (ddd, J = 14.5, 7.4, 4.3 Hz, 1 H), 1.65-1.72 (m, 1 H), 1.63 (d, J = 7.4 Hz, 3 
H), 1.56-1.60 (m, 2 H), 1.27 (s, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 130.2, 124.3, 73.9, 59.9, 
42.1, 41.6, 26.7, 21.6, 12.7; HRMS m/z 159.1386 (calcd for C9H18O2+H
+
, 159.1380). 
Compound 2-47 
A flask containing previously prepared Co(nmp)2 (0.062 g, 0.11 mmol, 
0.175 eq) was evacuated and refilled with oxygen.
 17
 iPrOH (3 mL) was 
introduced followed by tBuOOH (4 M in toluene, 0.03 mL, 0.11 mmol, 
0.175 eq) and the resulting solution was heated to 50 °C.
 18
 After 1 h the solvent removed under 
reduced pressure to afford oxidized Co(nmp)2 as green crystals. The flask containing the 
oxidized catalyst was then evacuated and refilled with oxygen. Pentenol 2-46 (0.104 g, 0.65 
mmol, 1 eq) in 2 mL sBuOH was then introduced and the resulting solution heated to 80 °C. 
After 16 h solvent was removed under reduced pressure and the residue passed through a plug of 
silica on Celite with excess EtOAc (50 mL). Solvent was then removed under reduced pressure 
and the residue purified by flash chromatography (80% EtOAc/Hexanes) to afford the title 
compound as a clear colourless oil (0.019 g, 17 %) as a complex mixture of diastereomers. 
1
H 
NMR (600 MHz, CDCl3) δ 5.12-5.14 (m, 1 H), 3.86-3.95 (m, 3 H), 3.73-3.82 (m, 1 H), 3.18-3.20 
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(m, 1 H), 1.68-1.95 (m, 6 H), 1.29 (s, 3 H), 1.11-1.88 (m, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 
84.2, 84.1, 83.4, 70.7, 67.6, 67.3, 59.8, 59.7, 58.4, 41.8, 41.7, 41.6, 38.3, 38.2, 37.7, 29.7, 27.8, 
26.7, 26.3, 25.7, 24.2, 24.1, 19.2, 18.4, 17.9; HRMS m/z 175.1339 (calcd for C9H18O3+H
+
, 
175.1329). 
Compound 2-51 
Epoxy alkene 2-43 (1.0g, 5.87 mmol, 1 eq) in THF (10 mL) was 
added to a suspension of LiAlH4 (0.334 g, 8.81 mmol, 1.5 eq) in THF 
(10 mL) at 0 °C. The resulting solution was allowed to warm to room temperature. After 5 h the 
reaction was cooled to 0 °C and diluted with ether (10 mL). Excess LiAlH4 was then quenched 
by the addition of water (10 mL). The layers were separated and the aqueous extracted with ether 
(3 x 20 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered 
through Celite and concentrated under reduced pressure. The residue (1.021 g) was then taken up 
in CH2Cl2 (50 mL). To the resulting solution were added imidazole (0.885 g, 13 mmol, 2.2 eq), 
TBSCl (0.889 g, 5.9 mmol, 1 eq), and DMAP (0.072 g, 0.59 mmol, 0.1 eq). After 2 h the 
reaction mixture was poured into half-saturated NH4Cl (100 mL). The layers were separated and 
the aqueous extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were washed with 
brine, dried over MgSO4, filtered through Celite and then concentrated under reduced pressure. 
The residue was purified by flash chromatography to afford the title compound as a clear 
colourless oil (1.50 g, 89% over 2 steps). Rf  0.8 (40% EtOAc/Hexanes); 
1
H NMR (600 MHz, 
CDCl3) δ 5.12-5.14 (m, 1 H), 3.87-3.93 (m, 2 H), 3.71 (s, 1 H), 1.98-2.10 (m, 2 H), 1.73-1.78 (m, 
1 H), 1.69 (s, 3 H), 1.63-1.68 (m, 1 H), 1.62 (s, 3 H), 1.45-1.56 (m, 2 H), 1.21 (s, 3 H), 0.90 (s, 9 
H), 0.09 (s, 6 H); 
13
C NMR (100 MHz, CDCl3) δ 131.4, 124.7, 72.6, 60.7, 42.3, 41.3, 26.4, 25.8, 
25.7, 22.7, 18.1, 17.6, -5.6; HRMS m/z 287.2406 (calcd for C16H34O2Si+H
+
, 287.2401). 
Compound 2-53 
To a solution of epoxy alkene 2-43 (0.50 g, 2.9 mmol, 1 eq) in 25 mL 
CH2Cl2 was added imidazole (0.592 g, 8.7 mmol, 3 eq). TIPSCl (0.9 
mL, 4.4 mmol, 1.5 eq) was then introduced and the resulting solution stirred for 2 h. The reaction 
mixture was then diluted with ether (25 mL) and the layers separated. The organic layer was 
washed with brine, water, dried over MgSO4, filtered through Celite and concentrated under 
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reduced pressure. The resulting crude material was then ozonized following the synthesis of 2-44 
and then subjected to Wittig olefination as carried out for 2-56 to afford after purification of the 
Wittig product by flash chromatography (5% EtOAc/Hexanes) the title compound as a clear 
colourless oil (0.866 g, 66% over 3 steps). Rf  0.75 (20% EtOAc/Hexanes); 
1
H NMR (600 MHz, 
CDCl3) δ 5.82 (dddd, J = 17.0, 10.0, 6.5, 6.5 Hz, 1 H), 5.02-5.05 (m, 1 H), 4.95-4.98 (m, 1 H), 
3.81 (dd, J = 7.6, 5.3 Hz, 2 H), 2.94 (t,  J = 5.2 Hz, 1 H), 2.12-2.22 (m, 2 H), 1.75 (ddd, J = 14.1, 
9.4, 5.9 Hz, 1 H), 1.53 (ddd,  J = 14.7, 10.0, 7.0 Hz, 1 H), 1.28 (s, 3 H), 1.06-1.12 (m, 21 H); 
13
C 
NMR (100 MHz, CDCl3) δ 137.9, 114.9, 63.3, 62.4, 60.2, 37.8, 29.4, 17.9, 16.7, 11.9; HRMS 
m/z 299.2407 (calcd for C17H34O2Si+H
+
, 299.2401). 
Compund 2-56 
KOtBu (3.37 g, 30 mmol, 2 eq) in 50 mL of toluene was cooled to 0 °C. 
To the resulting suspension was added methyltriphenylphosphonium 
bromide (10.72 g, 30 mmol, 2 eq) and the resulting yellow ylide solution stirred for 30 min. The 
ylide was cooled to – 78 °C and aldehyde 2-44 (3.87 g, 14.9 mmol, 1 eq) in 40 mL toluene was 
introduced. The resulting solution was stirred for 25 min at – 78 °C then allowed to warm to 0 
°C. After 1 h the reaction mixture was poured into water (50 mL). The layers were separated and 
the aqueous extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with 
brine, dried over MgSO4, filtered through Celite and concentrated under reduced pressure. The 
resulting crude material was purified by flash chromatography (2% EtOAc/Hexanes-
5%EtOAc/Hexanes) to afford the title compound as a clear colourless oil (2.62 g, 69%). Rf  0.58 
(10% EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3) δ 5.81 (dddd, J = 16.4, 10.0, 6.5, 6.5 Hz, 1 
H), 5.01-5.05 (m, 1 H), 4.95-4.98 (m, 1 H), 3.73 (dd, J = 5.3, 1.8 Hz, 2 H), 2.90 (t, J = 5.3 Hz, 1 
H), 2.11-2.21 (m, 2 H), 1.73 (ddd, J = 14.1, 9.4, 5.9 Hz, 1 H), 1.53 (ddd, J = 13.5, 10.0, 6.5 Hz, 1 
H), 1.27 (s, 3 H), 0.91 (s, 9 H), 0.09 (s. 3 H), 0.08 (s, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 137.9, 
114.9, 63.2, 62.2, 60.3, 37.8, 29.4, 25.9, 18.3, 16.7, -5.2, -5.4; HRMS m/z 257.1942 (calcd for 
C14H28O2Si+H
+
, 257.1931). 
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Compound 2-56  
Cross Metathesis Procedure: Grubb’s second generation catalyst 
(0.089 g, 0.11 mmol, 0.03 eq) was placed in a three neck flask equipped 
with a reflux condenser. The flask was evacuated and then re-filled with argon. CH2Cl2 (248 mL) 
was then introduced. Alkene 2-42 (1.0 g, 3.5 mmol, 1 eq) was introduced neat with a syringe and 
the syringe rinsed with CH2Cl2 (2 mL). The reaction vessel was cooled to –78 °C and ethylene 
was bubbled through the solution for 5 min. The reaction was placed under an atmosphere of 
ethylene (balloon) and then heated a 40 °C. After 24 h the flask was then allowed to cool to room 
temperature following which solvent was removed under reduced pressure. The residue was 
filtered through a plug of silica on Celite with EtOAc then concentrated under reduced pressure. 
The crude product containing (0.303 g, 1.06 mmol, 1 eq) of cross metathesis starting material as 
determined by NMR analysis of the crude reaction mixture was then taken up in CH2Cl2 (50 mL) 
and cooled to °C.  mCPBA (70%, 0.523 g, 2.12 mmol, 2 eq) was then introduced. After 30 min, 
half-saturated NaHCO3 (20 mL) was introduced. The layers were separated and the aqueous 
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were washed with brine, dried 
over MgSO4, filtered through Celite and concentrated under reduced pressure. The residue was 
purified by flash chromatography (3% EtOAc/Hexanes) to afford the title compound as a clear 
colourless oil (0.484 g, 54%).  
Compound 2-55 
To a suspension of LiAlH4 0.114 g, 3 mmol, 1.5 eq) in 20 mL THF was 
added epoxy alkene 2-56 (0.513 g, 2 mmol, 1 eq) in 10 mL THF and the 
resulting solution heated to reflux. After 12 h the reaction was allowed to cool to room 
temperature and excess LiAlH4 was quenched through the slow addition of water (20 mL).  The 
layers were separated and the aqueous extracted with EtOAc (3 x 50 mL). The combined organic 
layers were washed with brine, dried over MgSO4, filtered through Celite and concentrated under 
reduced pressure. The resulting crude material was purified by flash chromatography (70% 
EtOAc/Hexanes) to afford the title compound as a clear colourless oil (0.247g, 86%). Rf  0.16 
(40% EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3) δ 5.85 (dddd, J = 16.8, 10.2, 6.6, 6.6 Hz, 1 
H), 5.03-5.09 (m, 1  H), 4.96-4.99 (m, 1 H), 3.84-3.96 (m, 2 H), 2.46 (t, J = 5.1 Hz, 1 H), 2.26 (s, 
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1 H), 2.11-2.18 (m, 2 H), 1.81 (ddd, J = 14.8, 7.8, 4.7 Hz, 1 H), 1.60-1.72 (m, 3 H), 1.26 (s, 3 H); 
13
C NMR (100 MHz, CDCl3) δ 138.7, 114.6, 73.8, 59.8, 41.5, 28.4, 26.72, 26.65; HRMS m/z 
145.1225 (calcd for C8H16O2+H
+
, 145.1223). 
Compound 2-50 
 Alkene 2-56 (0.5 g, 1.9 mmol, 1 eq) and THF (15 mL) were combined 
in a flask equipped with a condenser. L-selectride (1M in THF, 3.8 mL, 
3.8 mmol, 2 eq) was introduced through the condenser and the resulting solution heated to 60 °C. 
After 20.5 h the reaction mixture was allowed to cool to room temperature. Water (10 mL) was 
introduced dropwise through the condenser. The layers were separated and the aqueous extracted 
with ether (3 x 30 mL). The combined organic layers were washed with brine, dried over 
MgSO4, filtered through Celite and concentrated under reduced pressure. The residue was 
purified by flash chromatography (8% EtOAc/Hexanes) to afford the title compound as clear 
colourless oil (0.446 g, 91%). Rf  0.55 (20% EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3) δ 
5.85 (dddd, J = 17.0, 10.0, 6.5, 6.5 Hz, 1 H), 5.02-5.05 (m, 1 H), 4.93-4.95 (m, 1 H), 3.90 (ddd, J 
= 11.7, 7.6, 4.1 Hz, 2 H), 3.77 (s, 1 H), 2.07-2.20 (m, 2 H), 1.76 (ddd, J = 14.7, 8.2, 4.7 Hz, 1 H), 
1.53-1.66 (m, 3 H), 1.21 (s, 3 H), 0.90 (s, 9 H), 0.09 (s, 6 H); 
13
C NMR (100 MHz, CDCl3) δ 
139.2, 114.1, 72.5, 60.7, 41.5, 41.3, 28.4, 26.3, 25.8, 18.1, -5.63; HRMS m/z 259.2088 (calcd for 
C14H30O2Si+H
+
, 259.2088). 
Compound 2-49 
A flask containing previously prepared Co(nmp)2 (0.170g, 0.3 mmol, 
0.175 eq) was evacuated and refilled with oxygen. iPrOH (3 mL) was 
introduced followed by tBuOOH (4 M in toluene, 0.08 mL, 0.3 mmol, 0.175 eq) and the 
resulting solution was heated to 50 °C. After 1 h the solvent removed under reduced pressure to 
afford oxidized Co(nmp)2 as green crystals. The flask containing the oxidized catalyst was then 
evacuated and refilled with oxygen. Pentenol 2-56 (0.462 g, 1 mmol, 1 eq) in 2 mL sBuOH was 
then introduced and the resulting solution heated to 80 °C. After 16 h solvent was removed under 
reduced pressure and the residue passed through a plug of silica on Celite with excess EtOAc (50 
mL). Solvent was then removed under reduced pressure and the resulting crude material purified 
by flash chromatography (20% EtOAc/Hexanes-40% EtOAc/Hexanes) to afford the title 
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compound as a clear colourless oil (0.198 g, 43 %) as a 3:1 mixture of diastereomers. Rf  0.35 
(40% EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3) δ [minor 4.09-4.13 (m, 1.0 H), 4.06 (dddd, 
J = 11.7, 5.9, 3.5, 3.5 Hz, 1 H), 3.67-3.81 (m, 5 H), [major 3.48 (dd, J = 11.2, 5.3 Hz, 1 H), 
minor 3.45 (dd, J = 11.2, 4.7 Hz, 1 H),] 1.88-1.97 (m, 4 H), 1.67-1.86 (m, 7 H), [major 1.23 (s, 3 
H), minor 1.22 (s, 1 H)], [minor 0.9 (s, 4 H), major 0.89 (s, 9 H)], [minor 0.06 (s, 2 H), major 
0.05 (s, 6 H)]; 
13
C NMR (100 MHz, CDCl3) δ 82.7, 82.6,79.0, 78.6, 65.2, 64.9, 60.0, 59.8, 44.0, 
43.5, 37.59, 37.55, 27.4, 27.2, 27.1, 26.2, 26.0, 25.9, 25.8, 18.34, 18.25, -5.3, -5.4; HRMS m/z 
275.2044 (calcd for C14H30O3Si+H
+
, 275.2037).  
Compound 2-57 
THF methanol 2-20 (.208 g, 0.76 mmol, 1 eq) was taken up in 
acetonitrile (3.8 mL) and water (3.8 mL). TEMPO (0.154 g, 1.0 
mmol, 1.3 eq) and BAIB (0.857 g, 2.66 mmol, 3.5 eq) were then introduced sequentially. After 
1.5 h the reaction mixture was diluted with EtOAc (5 mL) and water (5 mL). The layers were 
separated and the aqueous extracted with EtOAc (3 x 20 mL). The combined organic layers were 
dried over MgSO4, filtered through Celite and concentrated under reduced pressure. The residue 
(0.58 g, 2.01 mmol, 1 eq) was dissolved in toluene (16.1 mL) and freshly distilled MeOH (4.0 
mL) and cooled to 0 °C. Trimethylsilyldiazomethane (2M in Hexane, 1.2 mL, 2.4 mmol, 1.2 eq) 
was introduced and the cooling bath removed. After 1 h, the reaction mixture was concentrated 
under reduced pressure. The residue was purified by flash chromatography (10% 
EtOAc/Hexanes) to afford the title compound as a clear colourless oil (0.203 g, 88%) as a 3:1 
mixture of diastereomers. Rf  0.23 (10% EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3) δ [minor 
4.50 (d, J = 6.5 Hz, 0.14 H), major 4.48 (dd, J = 7.6, 6.5 Hz, 1 H)], 3.75-3.81 (m, 1 H), [major 
3.74 (s, 3 H), minor 3.73 (s, 3 H)], 3.69-3.73 (m, 1 H), 2.27-2.33 (m, 1 H), 2.09-2.14 (m, 1 H), 
1.93-1.98 (m, 1 H), 1.87-1.89 (m, 1 H), 1.69-1.83 (m, 4 H), [major 1.32 (s, 3 H), minor 1.24 (s, 3 
H)], [minor 0.89 (s, 9 H), major 0.88 (s, 9 H)], [major 0.05 (s, 6 H), major 0.04 (s, 6 H)]; 
13
C 
NMR (100 MHz, CDCl3) δ 174.0, 84.63,84.58,76.8, 76.4, 59.8, 59.7, 52.00, 51.95, 43.7, 43.5, 
36.7, 36.5, 30.3, 30.2, 26.3, 26.0, 25.9, 18.2, -5.39; HRMS m/z  303.1989 (calcd for 
C15H30O4Si+H
+
, 303.1986). 
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Compound 2-48 
Methylmagnesium bromide (3 M in ether, 0.48 mL, 1.45 mmol, 2.2 
eq) was introduced to a solution ester 2-57 (0.202 g, 0.66 mmol, 1 eq) 
in ether (13 mL) at 0 °C. The cooling bath was removed and the reaction allowed to stir 1.5 h. 
Excess Grignard reagent was then quenched through the slow addition of half-saturated NH4Cl 
(10 mL). The layers were separated and the aqueous extracted with ether (3 x 30 mL). The 
combine organic layers were washed with brine, dried over MgSO4, filtered through Celite, and 
concentrated under reduced pressure. The resulting crude material was purified by flash 
chromatography (10% EtOAc/Hexanes) to afford the title compound as a clear colourless oil 
(0.177 g, 89%) as a 3:1 mixture of diastereomers. Rf  0.53 (30% EtOAc/Hexanes); 
1
H NMR (600 
MHz, CDCl3) δ 3.71-3.81 (m, 4 H), 2.13 (s, 1 H), 1.91-1.74 (m, 7 H), 1.66-1.70 (m, 1 H), [minor 
1.21 (s, 6 H), major 1.20 (s, 6 H)], [major 1.12 (s, 3 H), minor 1.11 (s, 3 H)], [minor 0.90 (s, 9 
H), major  0.89 (s, 9 H)],[minor 0.064 (s, 3 H), minor 0.061 (s, 3 H), major 0.056 (s, 6 H)]; 
13
C 
NMR (100 MHz, CDCl3) δ 85.5, 84.9, 82.2, 82.1, 70.9, 70.7, 60.0, 59.9, 43.9, 43.8, 37.9, 37.8, 
27.64, 27.57, 26.9, 26.4, 26.3, 26.1, 26.0, 25.9, 24.3, 24.1, 18.4, 18.3, -5.32; HRMS m/z  
303.2358 (calcd for C16H34O3Si+H
+
, 303.2350). 
Compound 2-25 
10-CSA (0.005 g, 0.022 mmol, 0.04 eq) was introduced to THF alcohol 
2-48 (0.167 g, 0.55 mmol, 1 eq) in wet MeOH (7.1 mL) and THF (1.8 
mL) and the reaction monitored for completion by TLC. On depletion of the starting material the 
reaction mixture was poured into half-saturated NaHCO3 (10 mL). The layers were separated and 
the aqueous extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with 
brine, dried over MgSO4, filtered through Celite and concentrated under reduced pressure. The 
resulting crude material was purified by flash chromatography (80% EtOAc/Hexanes) to afford 
the title compound as a clear colourless oil (0.095 g, 92%) as a 3:1 mixture of diastereomers. Rf  
0.1 (50% EtOAc/Hexanes); 
1
H NMR (600 MHz, CDCl3) δ 3.92-3.95 (m, 0.2 H), 3.88-3.91 (m, 1 
H), 3.82 (dd, J = 9.4, 5.3 Hz, 1 H), 3.75-3.79 (m, 1 H), 3.22 (brs, 1 H), 1.76-2.00 (m, 6 H), 1.70-
1.74 (m, 1 H), 1.285 (s, 3 H), 1.28 (s, 1 H), 1.25 (s, 1 H), 1.23 (s. 1 H), 1.22 (s, 3 H), 1.125 (s, 3 
H), 1.20 (s, 1 H); 
13
C NMR (100 MHz, CDCl3) δ 86.3, 85.7, 84.4, 83.9, 70.9, 70.3, 59.9, 41.9, 
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41.7, 38.6, 38.2, 27.7, 26.4, 25.9, 25.7, 25.4, 25.0, 24.4; HRMS m/z  189.1481 (calcd for 
C10H20O3+H
+
, 189.1485). 
Compound 2-26 
 THF diol 2-25 (0.059 g, 0.31 mmol, 1 eq), iPr2NEt (0.36 mL, 2.1 mmol, 7 
eq), and DMSO (0.1 mL, 1.5 mmol, 5 eq) were combined in CH2Cl2 (6 
mL) at 0 °C. SO3•Pyr complex (0.148 g, 0.93 mmol, 3 eq) was then added in one portion and the 
cooling bath removed. After one hour the half-saturated NaHCO3 (10 mL) was introduced. The 
layers were separated and the aqueous extracted with CH2Cl2 (3 x 20 mL). The combined 
organic layers were washed with brine, dried over MgSO4, filtered through Celite and 
concentrated under reduced pressure. The residue was then purified by flash chromatography 
(50% EtOAc/Hexanes) to afford the title compound as a clear colourless oil (0.044g, 76%); Rf  
0.27 (50% EtOAc/Hexanes) 
1
H NMR (600 MHz, CDCl3) δ [ minor 9.85 (t, J = 3.1 Hz, 1 H), 
major 9.82 (t, J = 2.3 Hz, 1 H)], 3.80-3.85 (m, 1 H), 3.56-3.65 (m, 2 H), 2.00 (brs, 1 H), 1.80-
1.95 (m, 4 H), [minor 1.38 (s, 3 H), major 1.34 (s, 3 H), [minor 1.225 (s, 3 H), major 1.22 (s, 3 
H)], [major 1.13 (s, 3 H), 1.11 (s, 3 H)]; H); 
13
C NMR (100 MHz, CDCl3) δ 202.2, 202.1, 86.1, 
85.7, 81.2, 81.1, 71.0, 70.7, 54.2, 54.1, 38.1, 38.0, 27.6, 27.4, 27.3, 26.2, 26.0, 24.4, 24.1; HRMS 
m/z 185.1172 (calcd for C10H18O3– H
+
, 185.1172). 
Compound 2-15 
A Solution of THF Aldehyde 2-26 (0.052 g, 0.28 mmol, 1 eq) and 
tryptamine (0.045 g, 0.28 mmol, 1 eq) in CH2Cl2 (8 mL) was cooled 
to – 78 °C. TFA (0.04 mL, 0.56 mmol, 2 eq) was introduced and the 
solution allowed to warm to room temperature over 2 h. Saturated 
NaHCO3 (6 mL) was introduced and the layers separated. The aqueous was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic layers were dried over Na2SO4, filtered through 
Celite and concentrated under reduced pressure. The residue was purified by flash 
chromatography (10% MeOH/CH2Cl2) to afford tetrahydro-β-carboline 2-27 as an inseparable 
mixture of diastereomers (0.027 g). 2-27 (0.027 g, 0.08 mmol, 1 eq) was taken up in xylenes (2 
mL) and Pd/C (0.008 g) was introduced and the solution heated to reflux. After 1 h, the reaction 
mixture was allowed to cool to room temperature then filtered through Celite and concentrated 
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under reduced pressure. The residue was purified by flash chromatography (5% MeOH/CH2Cl2) 
to afford the title compound as an orange wax (0.016 g, 17% over 2 steps) as a 1.5:1 mixture of 
diastereomers. Rf  0.61 (20% MeOH/CH2Cl2); 
1
H NMR (600 MHz, CDCl3) δ 10.19 (brs 0.5 H), 
9.79 (s, 1 H), [ major 8.37 (d, J = 5.3 Hz, 1 H), minor 8.32 (m, 1 H)], [major 8.12 (d, J = 8.2 Hz, 
1 H), minor 8.08 (d, J = 8.2 Hz, 1 H)], [major, 7.86 (d, J = 5.3 Hz, 1 H), minor 7.81 (d, J = 4.7 
Hz, 1 H)], 7.50-7.54 (m, 2 H), 7.44 (d, J = 8.2 Hz, 1 H), 7.23-7.28 (m, 1 H), [minor 3.92 (dd, J = 
76, 5.9 Hz, 1 H), major 3.58 (dd, J = 10.0, 5.3 Hz, 1 H)], [major 3.53 (d, J = 14.7 Hz, 1 H), 
minor 3.49 (s, 2 H), major 3.42 (d, J = 14.7 Hz, 1 H)], 2.14 (brs, 1 H), 1.91-2.04 (m, 5 H), 1.71-
1.75 (m, 1 H), [Minor 1.31 (s, 3 H), major 1.32 (s, 3 H)], [major 1.28 (s, 3 H), minor 1.26 (m, 3 
H), minor 1.22 (s, 3 H), major 1.11 (s, 3 H)]; 
13
C NMR (100 MHz, CDCl3) δ 143.0, 140.9, 140.6, 
138.3, 135.87, 135.78, 129.0, 128.9, 128.21, 128.7, 122.0, 121.8, 121.7, 121.6, 119.8, 119.6, 
113.5, 113.2, 111.9, 111.7, 86.9, 86.4, 85.2, 84.1, 71.4, 70.3, 48.4, 39.0, 36.8, 28.2, 27.8, 27.6, 
26.18, 26.15, 25.9, 24.1; HRMS m/z 324.1836 (calcd for C20H24N2O2, 324.1838). 
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Appendix 1 – NMR Spectral Data for Chapter 1 
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Appendix 2 – NMR Spectral Data for Chapter 2 
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